Power of The Dream Ventures (PWRV) 10-Q 15 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 14, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Power of The Dream Ventures Inc	'
Entity Central Index Key	'0001377888	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	46,500,896
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash	$20,862	$22,922
Other receivables	188,187	217,419
Inventories	21,527	22,651
Total Current Assets	230,576	262,992
Intangibles	30,029,350	30,055,381
Fixed assets, net	147,329	189,194
Total Assets	30,407,255	30,507,567
Current Liabilities	'	'
Accounts payable and accrued and other liabilities	4,356,370	4,083,294
Grants received	-1,360,935	-1,432,042
Capital leases payable, current portion	69,446	55,784
Short term loans from related parties	73,907	86,899
Liability from warrants	91,480	87,502
Note payable	154,000	154,000
Short term loans	2,324,333	2,341,159
Total Current Liabilities	8,430,471	8,240,680
Long term liabilities	'	'
Capital leases payable, less current portion	'	35,692
Total Long Term Liabilities	'	35,692
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 5,450,000 and 4,900,000 issued of which Series “A”, of which Series “B”, of which Series “C”, of which Series “D”, of which Series “E”	5,450	4,900
Common stock, $0.001 par value; 100,000,000 shares authorized, 46,500,896 and 46,500,896 shares issued and outstanding	46,501	46,501
Additional Paid-In Capital	35,780,684	35,403,285
Deficit accumulated during development stage	13,764,235	13,018,339
Other Comprehensive Income	-91,616	-205,152
Total Stockholders' Equity	21,976,784	22,231,195
Total liabilities and stockholders' equity	30,407,255	30,507,567
Series A Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 5,450,000 and 4,900,000 issued of which Series “A”, of which Series “B”, of which Series “C”, of which Series “D”, of which Series “E”	2,000	2,000
Total Stockholders' Equity	2,000	2,000
Total liabilities and stockholders' equity	2,000	2,000
Series B Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 5,450,000 and 4,900,000 issued of which Series “A”, of which Series “B”, of which Series “C”, of which Series “D”, of which Series “E”	1,000	1,000
Total Stockholders' Equity	1,000	1,000
Total liabilities and stockholders' equity	1,000	1,000
Series C Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 5,450,000 and 4,900,000 issued of which Series “A”, of which Series “B”, of which Series “C”, of which Series “D”, of which Series “E”	1,000	900
Total Stockholders' Equity	1,000	900
Total liabilities and stockholders' equity	1,000	900
Series D Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 5,450,000 and 4,900,000 issued of which Series “A”, of which Series “B”, of which Series “C”, of which Series “D”, of which Series “E”	1,000	1,000
Total Stockholders' Equity	1,000	1,000
Total liabilities and stockholders' equity	1,000	1,000
Series E Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 5,450,000 and 4,900,000 issued of which Series “A”, of which Series “B”, of which Series “C”, of which Series “D”, of which Series “E”	450	'
Total Stockholders' Equity	450	'
Total liabilities and stockholders' equity	$450	'

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred Stock, par value per share	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	5,450,000	4,900,000
Preferred Stock, shares outstanding	5,450,000	4,900,000
Common Stock, par value per share	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	46,500,896	46,500,896
Common Stock, shares outstanding	46,500,896	46,500,896

Consolidated_Statement_Of_Oper

Consolidated Statement Of Operations (USD $)	3 Months Ended		6 Months Ended		98 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Income Statement [Abstract]	'	'	'	'	'
Net Sales	'	'	'	'	$5,833
Cost of Sales	'	'	'	'	3,711
Gross margin	'	'	'	'	2,122
Material expenses	12,567	24,495	18,448	49,398	164,122
General administration	198,502	347,591	395,612	503,058	9,290,844
Research and development	'	'	'	'	866,619
Personnel expenses	24,607	136,317	44,413	277,095	1,010,017
Depreciation and amortization	29,548	36,837	56,433	74,016	763,714
Grants received	61,358	-266	34,859	28,516	311,838
Other expenses, net	-127,163	-19,883	19,838	-568,759	733,796
Operating expenses	76,703	525,623	499,885	306,292	12,517,274
Profit (Loss) from operations	-76,703	-525,623	-499,885	-306,292	-12,515,152
Interest expense and exchange differences	158,478	92,280	246,011	183,900	1,044,368
Profit (Loss) before income taxes	-235,181	-617,903	-745,896	-490,192	-13,559,520
Income taxes	'	'	'	'	3,952
Net profit (loss)	-235,181	-617,903	-745,896	-490,192	-13,563,472
Other comprehensive income	39,507	-135,567	113,536	-55,025	'
Total comprehensive income	($195,674)	($753,470)	($632,360)	($545,217)	'
Basic loss per share	$0	($0.01)	($0.01)	($0.01)	'
Diluted loss per share	$0	($0.01)	($0.01)	($0.01)	'
Weighted average number of shares outstanding - Basic	45,500,896	45,033,548	46,500,896	43,771,408	'
Weighted average number of shares outstanding - Diluted	45,500,896	45,033,548	46,500,896	43,771,408	'

Consolidated_Statement_Of_Stoc

Consolidated Statement Of Stockholders' Equity And Comprehensive Loss (USD $)	Preferred Stock	Common Stock	Accumulated Deficit During Development Stage	Additional Paid-In Capital	Other Comprehensive Income	Unearned Compensation	Total	Comprehensive Income / Loss
Balance, Amount at Apr. 25, 2006	'	'	'	'	'	'	'	'
Issuance of common stock, Shares	'	33,300,000	'	'	'	'	'	'
Issuance of common stock, Amount	'	$3,330	'	$10,670	'	'	$14,000	'
Contributed Capital	'	'	'	96,100	'	'	96,100	'
Currency Translation Adjustment	'	'	'	'	4,151	'	4,151	4,151
Net loss for the period	'	'	-35,100	'	'	'	-35,100	-35,100
Balance, Amount at Dec. 31, 2006	'	3,330	-35,100	106,770	4,151	'	79,151	-30,949
Balance, Shares at Dec. 31, 2006	'	33,300,000	'	'	'	'	'	'
Contributed Capital	'	'	'	53,735	'	'	53,735	'
Currency Translation Adjustment	'	'	'	'	-14,001	'	-14,001	-14,001
Recapitalization upon Reverse Merge, Shares	'	2,500,000	'	'	'	'	'	'
Recapitalization upon Reverse Merge, Amount	'	250	-250,763	'	'	'	-250,513	'
Private placement, Shares	'	2,354,000	'	'	'	'	'	'
Private placement, Amount	'	235	'	1,024,765	'	'	1,025,000	'
Shares issued for services, Shares	'	1,875,000	'	'	'	'	'	'
Shares issued for Services, Amount	'	188	'	637,313	'	-467,501	170,000	'
Shares issued for research and development, Shares	'	100,000	'	'	'	'	'	'
Shares issued for research and development, Amount	'	10	'	33,990	'	'	34,000	'
Shares issued for stock based compensation, Shares	'	1,036,000	'	'	'	'	1,036,000	'
Shares issued for stock based compensation, Amount	'	104	'	2,589,896	'	-2,590,000	'	'
Amortization of Unearned Compensation	'	'	'	'	'	1,124,932	1,124,932	'
Net loss for the period	'	'	-1,992,472	'	'	'	-1,992,472	-1,992,472
Balance, Amount at Dec. 31, 2007	'	4,117	-2,278,335	4,446,469	-9,850	-1,932,569	229,832	-2,006,473
Balance, Shares at Dec. 31, 2007	'	41,165,000	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	'	36,465	'	36,465	36,465
Private placement, Shares	'	2,532,500	'	'	'	'	'	'
Private placement, Amount	'	253	'	1,105,372	'	'	1,105,625	'
Shares issued for services, Shares	'	1,917,681	'	'	'	'	'	'
Shares issued for Services, Amount	'	192	'	1,489,407	'	-1,489,599	'	'
Amortization of Unearned Compensation	'	'	'	'	'	3,018,710	3,018,710	'
Shares issued for standby equity distribution agreement, Shares	'	2,000,000	'	'	'	'	'	'
Shares issued for standby equity distribution agreement, Amount	'	200	'	-200	'	'	'	'
Net loss for the period	'	'	-3,958,212	'	'	'	-3,958,212	-3,958,212
Balance, Amount at Dec. 31, 2008	'	4,762	-6,236,547	7,041,048	26,615	-403,458	432,420	-3,921,747
Balance, Shares at Dec. 31, 2008	'	47,615,181	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	'	17,823	'	17,823	17,823
Private placement, Shares	'	286,110	'	'	'	'	'	'
Private placement, Amount	'	29	'	50,193	'	'	50,222	'
Shares issued for services, Shares	'	250,000	'	'	'	'	'	'
Shares issued for Services, Amount	'	25	'	99,975	'	-60,000	40,000	'
Shares issued for stock based compensation, Shares	'	700,000	'	'	'	'	700,000	'
Shares issued for stock based compensation, Amount	'	70	'	279,930	'	-280,000	'	'
Amortization of Unearned Compensation	'	'	'	'	'	728,458	728,458	'
Net loss for the period	'	'	-1,518,077	'	'	'	-1,518,077	-1,518,077
Balance, Amount at Dec. 31, 2009	'	4,886	-7,754,624	7,471,146	44,438	-15,000	-249,154	-1,500,254
Balance, Shares at Dec. 31, 2009	'	48,851,291	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	'	-38,874	'	-38,874	-38,874
Private placement, Shares	'	1,667,500	'	'	'	'	'	'
Private placement, Amount	'	166	'	194,535	'	'	194,701	'
Shares issued for services, Shares	'	1,047,000	'	'	'	'	'	'
Shares issued for Services, Amount	'	102	'	515,398	'	-515,500	'	'
Shares issued for stock based compensation, Shares	'	540,000	'	'	'	'	540,000	'
Shares issued for stock based compensation, Amount	'	54	'	53,946	'	-54,000	'	'
Amortization of Unearned Compensation	'	'	'	'	'	200,528	200,528	'
Exercise of warrant, Shares	'	3,226	'	'	'	'	'	'
Exercise of warrant, Amount	'	3	'	1,613	'	'	1,616	'
Net loss for the period	'	'	-588,910	'	'	'	-588,910	-588,910
Balance, Amount at Dec. 31, 2010	'	5,211	-8,343,534	8,236,638	5,564	-383,972	-480,093	-627,784
Balance, Shares at Dec. 31, 2010	'	52,109,017	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	'	-13,791	'	-13,791	-13,791
Private placement, Shares	'	1,969,027	'	'	'	'	'	'
Private placement, Amount	'	197	'	339,676	'	'	339,873	'
Shares issued for services, Shares	'	1,970,000	'	'	'	'	'	'
Shares issued for Services, Amount	'	197	'	457,691	'	-457,888	'	'
Shares issued for stock based compensation, Shares	'	540,000	'	'	'	'	540,000	'
Shares issued for stock based compensation, Amount	'	54	'	80,946	'	-81,000	'	'
Amortization of Unearned Compensation	'	'	'	'	'	781,458	781,458	'
Conversion of note, Shares	'	5,900,000	'	'	'	'	'	'
Conversion of note, Amount	'	590	'	89,410	'	'	90,000	'
Cancellation of common stock (and issue of preferred stock), Shares	2,000,000	-24,000,000	'	'	'	'	'	'
Net loss for the period	'	'	-1,251,035	'	'	'	-1,251,035	-1,251,035
Balance, Amount at Dec. 31, 2011	'	6,249	-9,594,569	9,204,361	-8,227	-141,402	-533,588	-1,264,826
Balance, Shares at Dec. 31, 2011	2,000,000	38,488,044	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	'	-37,272	'	-37,272	-37,272
Private placement, Shares	'	42,200	'	'	'	'	'	'
Private placement, Amount	'	4	'	12,654	'	'	12,658	'
Shares issued for services, Shares	'	2,065,000	'	'	'	'	'	'
Shares issued for Services, Amount	'	1,944	'	199,826	'	-132,850	'	'
Amortization of Unearned Compensation	'	'	'	'	'	197,328	197,328	'
Conversion of note, Shares	'	1,900,000	'	'	'	'	'	'
Conversion of note, Amount	'	1,900	'	74,100	'	'	76,000	'
Conversion of common shares to preferred shares (change in value)	'	-2,200	'	2,200	'	'	'	'
Change of par value	'	36,598	'	-36,598	'	'	'	'
Acquisition of genetic immunity, Shares	1,000,000	'	'	'	'	'	'	'
Acquisition of genetic immunity, Amount	1,000	'	50,000	25,023,620	'	'	25,074,620	'
Net loss for the period	'	'	-1,679,052	'	'	'	-1,679,052	-1,679,052
Balance, Amount at Dec. 31, 2012	'	45,495	-11,223,621	34,480,163	-45,499	-76,924	23,179,614	-1,716,324
Balance, Shares at Dec. 31, 2012	3,000,000	42,495,244	'	'	'	'	42,495,244	'
Issuance of common stock, Shares	'	1,000,000	'	'	'	'	'	'
Issuance of common stock, Amount	'	1,000	'	159,000	'	'	160,000	'
Currency Translation Adjustment	'	'	'	'	-159,653	'	-159,653	-159,653
Private placement, Shares	1,900,000	2,500,000	'	'	'	'	'	'
Private placement, Amount	1,900	2,500	'	735,753	'	'	740,153	'
Shares issued for services, Shares	'	100,000	'	'	'	'	'	'
Shares issued for Services, Amount	'	100	'	19,800	'	'	19,900	'
Shares issued for stock based compensation, Amount	'	'	'	'	'	'	'	'
Amortization of Unearned Compensation	'	'	'	'	'	41,899	41,899	'
Conversion of note, Shares	'	655,652	'	'	'	'	'	'
Conversion of note, Amount	'	656	'	43,344	'	'	44,000	'
Cancellation of shares for services, Shares	'	-250,000	'	'	'	'	'	'
Cancellation of shares for services, Amount	'	-250	'	-34,775	'	35,025	'	'
Net loss for the period	'	'	-1,794,718	'	'	'	-1,794,718	-1,794,718
Balance, Amount at Dec. 31, 2013	'	51,401	-13,018,339	35,403,285	-205,152	'	22,231,195	-1,954,371
Balance, Shares at Dec. 31, 2013	4,900,000	46,500,896	'	'	'	'	46,500,896	'
Currency Translation Adjustment	'	'	'	'	113,536	'	113,536	'
Private placement, Shares	550,000	'	'	'	'	'	'	'
Private placement, Amount	550	'	'	377,399	'	'	377,949	'
Shares issued for Services, Amount	'	'	'	'	'	'	'	'
Shares issued for stock based compensation, Amount	'	'	'	'	'	'	'	'
Net loss for the period	'	'	-745,896	'	'	'	-745,896	'
Balance, Amount at Jun. 30, 2014	'	$51,951	($13,764,235)	$35,780,684	($91,616)	'	$21,976,784	'
Balance, Shares at Jun. 30, 2014	5,450,000	46,500,896	'	'	'	'	46,500,896	'

Consolidated_Statement_Of_Cash

Consolidated Statement Of Cash Flows (USD $)	6 Months Ended		98 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net profit (loss)	($745,896)	($490,192)	($13,563,472)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Amortization of stock-based compensation	'	20,899	6,308,238
Recapitalization under reverse merger	'	'	-250,763
Issue of shares for services	'	'	210,000
Issue of shares for research and development	'	'	34,000
Liability from warrant	3,978	-568,766	91,480
Reversal of grant accrual	'	'	-245,306
Depreciation and amortization	56,433	74,016	763,714
Total adjustments to reconcile net income loss to cash provided by operating activities before changes in operating assets and liabilities	-685,485	-964,043	-6,652,109
Changes in operating assets and liabilities:	'	'	'
(Increase) Decrease in other current assets	-30,356	-73,470	209,714
(Decrease) Increase in accounts payable and accrued liabilities	174,576	803,263	3,786,960
Net cash used in operating activities	-480,553	-87,310	-3,074,863
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of fixed assets	'	'	702,413
Net cash used in investing activities	'	'	-702,413
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from stockholders	'	'	212,033
Increase (Decrease) in related party liabilities	-12,992	91,435	73,907
Exercise of warrant	'	'	1,616
Proceeds from sale of preferred stock	377,949	'	646,949
Proceeds from sale of common stock	'	52,500	2,885,249
Proceeds from issuance of notes	'	'	70,000
Net cash from financing activities	364,957	143,935	3,889,754
Effect of exchange rate changes on cash	113,536	-55,025	-91,616
Net (decrease) increase in cash	-2,060	1,600	20,862
Cash at beginning of period	22,922	63,986	'
Cash at end of period	20,862	65,586	20,862
Non-cash investing and financing transactions	'	'	'
Issuance of shares for services	'	19,900	4,256,158
Issuance of shares for liabilities assumed under reverse merger	'	'	250,513
Issuance of stock based compensation shares	'	'	2,590,000
Purchase of fixed assets through the assumption of capital lease obligations	'	406,558	406,558
Cash paid for Interest	'	'	40,980
Cash paid for Taxes	'	'	'

General_Information

General Information	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
General Information	'
	NOTE 1 - GENERAL INFORMATION
	Power of the Dream Ventures, Inc., f/k/a “Tia V, Inc.” (“PDV” or the “Company”) was incorporated in Delaware on August 17, 2006, with the objective to acquire, or merge with, an operating business.
	Reverse merger
	PDV entered into and consummated a Securities Exchange Agreement (“Exchange Agreement”) on April 10, 2007. Under the terms of the Exchange Agreement, PDV acquired all the outstanding equity interests of Vidatech, Kft. (also known as Vidatech Technological Research and Development LLC) a limited liability company formed under the laws of the Republic of Hungary, (“Vidatech”) in exchange for 33,300,000 shares of PDV’s common stock, and Vidatech thereby became a wholly-owned Hungarian subsidiary of PDV. PDV is governed by the law of the State of Delaware, and its wholly-owned subsidiary, Vidatech, is governed by the law of the Republic of Hungary. PDV and Vidatech are herein collectively referred to as the “Company.”
	Following the acquisition the former stockholders of Vidatech owned a majority of the issued and outstanding common stock of PDV and the management of Vidatech controlled the Board of Directors of PDV and its wholly-owned Hungarian subsidiary Vidatech. Therefore the acquisition has been accounted for as a reverse merger (the “Reverse Merger”) with Vidatech as the accounting acquirer of PDV. The accompanying consolidated financial statements of the Company reflect the historical results of Vidatech, and the consolidated results of operations of PDV subsequent to the acquisition date. In connection with the Exchange Agreement, PDV adopted the fiscal year end of Vidatech as December 31.
	All reference to shares and per share amounts in the accompanying consolidated financial statements have been restated to reflect the aforementioned shares exchange.
	Genetic Immunity
	On October 2, 2012 the Company acquired Genetic Immunity, Inc., a US corporation domiciled in the state of Delaware. Genetic Immunity is an immunotherapeutic vaccine company whose lead product candidate DermaVir, for the treatment of HIV, has passed Phase II clinical trials.
	Through the acquisitions Genetic Immunity became 100% wholly owned subsidiary. The acquisition was completed for 1,000,000 shares of Series B Preferred stock, convertible into 40 million shares of common stock beginning on January 1, 2014.
	The Company filed an 8-K with the SEC disclosing this transaction on October 4, 2012.
	The acquisition of Genetic Immunity, Inc. has been accounted for as a business combination whereby the purchase price was allocated to intangible assets based on their fair values of the acquisition date. A summary of the purchase price consideration and related purchase price allocation are shown below:
	Purchase price (at par value)			$	1
	Fair value adjustment of shares				25,072,621
	Total purchase price				25,073,621
	The fair value of the shares equals the fair value of Genetic Immunity, Inc. at the acquisition date. The fair value of the company was estimated by an independent valuation company and the valuation was carried out on a discounted cash flow basis. The Company issued 1,000,000 shares of Series B Preferred stock which is not traded publicly and no market price could be estimated. As a result of this, the fair value of the shares was evaluated by a valuation company. The value of the shares is $25.07362 per share.
	Purchase price allocation
	Cash		$	357,276
	Inventories			13,843
	Other receivables			306,731
	Intangibles			30,111,909
	Fixed assets			418,483
	Accounts payable and accrued liabilities			(1,893,833	)
	Grants received			(1,677,348	)
	Short term loans to related parties			(154,631	)
	Bridge loan			(2,334,326	)
	Other liabilities			(73,483	)
	Total purchase price			25,074,621
	Business
	The Company is engaged in the acquisition, development, licensing and commercialization of and the investment in, directly or through business acquisitions, technologies developed in Hungary. In furtherance of its business, the Company provides research and development services to the companies, inventors from whom it acquires technologies or participation interests in technologies. A goal of the Company is to support research and development activities and to sell the products of inventions to the technological market.
	From inception through June 30, 2014, the Company primarily focused on the raising of capital. As of June 30, 2014, the Company originally managed seven technologies: RiverPower, the Buresch Inventions (Desalination and H2O gas technology,) the Kalmar inventions (FireSAFE fire-proofing liquid; technology for utilizing communal waste as a concrete additive; technology for repairing potholes with the use of recycled plastics; technology for neutralizing red mud; biodegradable deicing solution and PVC shielded electric cable recycling technology), and an equity interest in ‘iGlue, Inc (Ticker: IGLU)’, a company formed to develop next generation semantic internet based search engine and content organizer applications. As of June 30, 2014 the Company has discontinued efforts to develop the Buresch inventions, the Kalmar inventions, RiverPower and the Toth Telescope. (see Note 4). As of June 30, 2014, the Company has only realized limited revenues from the now discontinued TothTelescope project and has not realized any revenues from the other, now discontinued inventions. As a result, the accompanying consolidated financial statements have been presented on a development stage basis.
	The Kalmar Inventions: FireSAFE, HardCrete concrete from communal waste additive; Recycled plastic pothole filler; PVC covered electrical cable and radial tire recycling technology; red mud neutralization; and environmentally friendly salt free de-icing solution.
	As of December 31, 2011 the Company elected to discontinue development work on all of these technologies. The rational behind this decision rests with availability of resources, the time that would be needed to develop said inventions, the potential return the Company could realize on a partial or full exit from these investments and international completion.
	TothTelescope
	On July 15, 2009 the Company’s exclusive distributor agreement expired with Attila Toth, Inventor of the TothTelescope. After extensive review of the technology, the available market and hurdles associated with manufacturing and distributing the TothTelescope, we have elected not to renew the distribution agreement and discontinue the project. Since inception only 10 telescopes were sold. Overall invested capital was returned from commissions earned on these sales.
	Yorkville SEDA
	On October 8, 2008, Power of the Dream Ventures, Inc. (the “Company”) entered into a Standby Equity Distribution Agreement (the “Standby Equity Distribution Agreement”) with YA Global Investments, L.P. (the “Investor”). Pursuant to the terms of the Standby Equity Distribution Agreement, the Company (a) agreed to issue and sell to the Investor up to $5,000,000 of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) in tranches of equity, based upon a specified discount to the market price of the Common Stock, calculated over the five trading days following notice by the Company of an election to sell shares; and (b) issued to the Investor a warrant (the “Warrant”) to purchase 4,027,386 shares of Common Stock at the exercise price per share of $0.29. The Warrant is not part of the commitment shares issued by the company to the investor. The investor must purchase the shares underlying the Warrant. The Warrant price was determined based upon the highest Bid price on the day of the closing of the agreement.
	In connection with the Standby Equity Distribution Agreement, the Company entered into a Registration Rights Agreement with the Investor (the “Registration Rights Agreement”) pursuant to which the Company agreed to register for resale the shares of Common Stock that may be purchased by the Investor pursuant to the Standby Equity Distribution Agreement, the shares of Common Stock issuable upon exercise of the Warrant and 2,000,000 shares of Common Stock (the “Commitment Shares”) issued to the Investor as a commitment fee pursuant to the terms of the Standby Equity Distribution Agreement. The commitment fee is recorded by decreasing additional paid in capital.
	Financing from this transaction will be used by the Company for the continued development of its current technologies, commercialization of same, the acquisition of new technologies and for general corporate expenses.
	The Company filed the details of this transaction on Form 8-K with the Commission on October 14, 2008.
	On September 24, 2010 the Company notified YA Global Investments in writing of its intention to terminate the Standby Equity Distribution Agreement (SEDA).
	In response to this letter YA Global informed the company in a letter dated October 5, 2010 that the SEDA agreement will terminate on or about October 15, 2010. YA Global also informed the company that even though the SEDA agreement is terminated its associated Warrant to purchase 4,027,386 shares of common stock remains in effect until it expired on October 8, 2013.
	On October 18, 2010 the company received notice from YA global for the exercise of 50,000 warrant shares on a cashless basis. This cashless exercise resulted in the issuance of 3,226 shares of Common stock to YA Global. Following this exercise YA Global has 3,977,386 warrant shares available for purchase.
	iGlue Software via Equity position in iGlue, Inc.
	From 2007 to 2011 the Company funded the development of iGlue, the cornerstone of the current technology portfolio. The financial commitment to in4, Ltd, the company behind iGlue, amounted to a total of approximately $600,000 for years 2007 through 2010. The total chronological events of iGlue are:
		•	On August 2, 2007 Vidatech Kft., the Company’s wholly owned Hungarian subsidiary, entered into a joint development agreement with the inventors/creators of iGlue, an online content organization and search application based on semantic web technology. In the transaction Vidatech received 30% equity in the newly formed in4 Kft (http://www.in4.hu), the owner and exclusive developer of iGlue (http://www.iglue.com), for HUF 900 thousand (approximately USD 5,000). Up until May 31, 2009, Vidatech was expected to provide up to HUF 48 million (approximately USD 271,000) in member loans to in4 Kft. to cover the development expense of iGlue.
		•	As of December 31, 2008 the Company has provided this amount to in4, Ltd.
		•	As part of the agreement, Vidatech had the option of converting its HUF 48 million member loan into an additional 10% equity in in4 Kft. on or before the end of May, 2009. As of January 8, 2009 the Company has elected to covert our member loan into the additional 10% equity in in4, Ltd., resulting in Vidatech owning 40% of equity.
		•	On May 17th, 2010, the Company transferred its equity ownership from its Hungarian subsidiary Vidatech, Kft. to Power of the Dream Ventures. The transfer was initiated to prepare for its eventual exit from iGlue.
		•	Also on May 17th, 2010, the Company arranged for a new investor to provide further funds for the continued development of iGlue, in the amount of HUF 110 million (approximately USD 550,000.) Prior to this event, up to May 17th, 2010 the Company has provided an additional HUF 64million ($310,000) as member loan to in4 Ltd. to finance development work, bringing our total investment to date to HUF 112,000,000 (approximately $600,000). As part of the new round of fund raising the Company agreed to convert its HUF 60 million in member loan into 3% equity. Following this conversion the new investor received 10% in in4, Ltd., of which the Company provided 1.5% and Peter Vasko, Founder of in4 limited provided 8.5%. Following the fund raising the new equity positions in in4 changed to Peter Vasko owning 51.5% (down from the pre-transaction 60%), Power of the Dream Ventures owning 38.5% (down from the pre-transaction 40%) and the new investor owning 10% equity.
		•	On May 19 of 2011 a new member joined in4, Ltd, Zoltan Siklosi who received 3% equity in the company for services rendered. Following his entry the new equity structure of the company changed to Peter Vasko owning 48.5% percent, Gyorgy Markos owning 10%, Zoltan Siklosi owning 3% and Power of the Dream Ventures owning 38.5%.
		•	Subsequently, to take iGlue to the next level, the Company organized a going public roadmap for the company. As part of this process, on November 3, 2011, in4, Ltd signed a Definitive Share Exchange Agreement to merge with Hardwired Interactive (HDWR) a fully reporting public company. As part of this agreement all holders of in4, Ltd equity received common and preferred stock in the newly public entity. As part of the transaction we received 600,000 shares of Series B Hardwired Interactive common stock convertible into 6,000,000 shares of common stock upon a reverse stock split. The Company also received warrants to purchase a total of three million shares of post split common stock, one million shares each at $5 dollars, $7 dollars and $9 dollars per share.
		•	On November 23, 2011 the Company announced plans to provide a dividend, in the form of iGlue common stock, to PWRV shareholders of record on December 23, 2011. Each PWRV share was to receive 0.05 share of iGlue common stock in the dividend. Upon approval from FINRA this dividend was paid out to PWRV shareholders on February 15, 2012. Following this distribution the Company still holds 2,884,986 shares of iGlue common stock and warrants to purchase a total of three million addition shares.
	Basis of presentation
	The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America for financial information have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading as of and for the period ended June 30, 2014 and for the period from April 26, 2006 (date of inception) to June 30, 2014.
	Going Concern and Management’s Plan
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate the continuation of the Company as a going concern and assume realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses from operations since inception. Management anticipates incurring additional losses in 2014. Further, the Company may incur additional losses thereafter, depending on its ability to generate revenues from the licensing or sale of its technologies and products, or to enter into any or a sufficient number of joint ventures. The Company has minimal revenue to date. There is no assurance that the Company can successfully commercialize any of its technologies and products and realize any revenues therefore. The Company’s technologies and products have never been utilized on a large-scale commercial basis and there is no assurance that any of its technologies or products will receive market acceptance. There is no assurance that the Company can continue to identify and acquire new technologies.
	Since inception through June 30, 2014, the Company had an accumulated deficit of $13,764,235 and net cash used in operations of $3,074,863. However, management of the Company believes that future funding from the private placement of the Company’s common shares will allow them to continue operations and execute its business plan.
	During 2014 and 2013 the Company raised a total of $377,949 and $401,500, respectively through private placements of common and preferred stock. These funds were used to finance operations, to reduce Genetic Immunity debt, and to finance Genetic Immunity’s regulatory process towards a marketing approval application. Additional funds used for these tasks, in the amount of $337,657 were previously provided in the prior years by the director, Peter Boros, who elected in November of 2013 to convert said loan into 1,000,000 shares of our Series D Preferred Stock.
	On March 16, 2011 the Company entered into a Convertible Promissory Note with Infinite Funding LLC whereby Infinite Funding provided $76,000 dollars in loans to the Company. The note bears interest at 10%, is due December 5, 2011, and is convertible into shares of common stock at a conversion price of $0.04. On December 4, 2011 we received an extension to this note to December 31, 2012. The note was converted to 1,900,000 common shares at September 30, 2012.
	On July 19, 2011 the Company entered into a Convertible Promissory Note with Infinite Funding LLC whereby Infinite Funding provided $49,000 dollars in loans to the Company. The note bears interest at 12%.
	Management believes the Company has adequate capital to keep the Company functioning through June 30, 2015. As discussed in contingencies, the Company anticipates receiving funds from the Hungarian state pursuant to the lawsuit it has filed to recover the awards granted to the Company plus damages. Also, additional fund raisings are in progress. However, the Company cannot guarantee that any amount from the lawsuit will be recoverable nor that any fund raising activities will be successful. The need may arise, in the normal course of business, to raise additional capital if we want to accelerate development work, for the acquisition of additional technologies, or to meet unforeseen financial needs. No assurance can be given that the Company can obtain additional working capital, or if obtained, that such funding will not cause substantial dilution to shareholders of the Company. If the Company is unable to raise additional funds, if needed, it may be forced to change or delay its contemplated marketing and business plan. Being a development stage company, the Company is subject to all the risks inherent in the establishment of a new enterprise and the marketing and manufacturing of a new product, many of which risks are beyond the control of the Company. All of the factors discussed above raise substantial doubt about the Company’s ability to continue as a going concern.
	These consolidated financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary as a result of the above uncertainty.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The significant accounting policies adopted in preparation of the consolidated financial statements are set out below.
	Principles of Consolidation
	The consolidated financial statements include the accounts of PDV and its wholly-owned Hungarian subsidiary, Vidatech. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates:
	The preparation of the financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect amounts reported herein. Management believes that such estimates, judgments and assumptions are reasonable and appropriate. However, due to the inherent uncertainty involved, actual results may differ from those based upon management’s judgments, estimates and assumptions. Critical accounting policies requiring the use of estimates are depreciation and amortization and share-based payments
	Revenue Recognition:
	Sales are recognized when there is evidence of a sales agreement, the delivery of the goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured, generally upon shipment of product to customers and transfer of title under standard commercial terms. Sales are measured based on the net amount billed to a customer. Generally there are no formal customer acceptance requirements or further obligations. Customers do not have a general right of return on products shipped therefore no provisions are made for return.
	Accounts Receivable and Allowance for Doubtful Accounts:
	Accounts receivable are stated at historical value, which approximates fair value. The Company does not require collateral for accounts receivable. Accounts receivable are reduced by an allowance for amounts that may be uncollectible in the future. This estimated allowance is determined by considering factors such as length of time accounts are past due, historical experience of write offs, and customers’ financial condition.
	Inventories:
	Inventories are stated at the lower of cost, determined based on weighted average cost or market. Inventories are reduced by an allowance for excess and obsolete inventories based on management’s review of on-hand inventories compared to historical and estimated future sales and usage.
	Fixed assets:
	Fixed assets are stated at cost or fair value for impaired assets. Depreciation and amortization is computed principally by the straight-line method. Asset amortization charges are recorded for long lived assets. In the related periods, no asset impairment charges were accounted for. Depreciation is recorded commencing the date the assets are placed in service and is calculated using the straight line basis over their estimated useful lives.
	The estimated useful lives of the various classes of long-lived assets are approximately 3-7 years.
	Pensions and Other Post-retirement Employee benefits:
	In Hungary, pensions are guaranteed and paid by the government or by pension funds, therefore no pensions and other post-retirement employee benefit costs or liabilities are to be calculated and accounted by the Company.
	Product warranty:
	The Company accrues for warranty obligations for products sold based on management estimates, with support from sales, quality and legal functions, of the amount that eventually will be required to settle such obligations. At June 30, 2014, the Company had no warranty obligations in connection with products sold.
	Advertising costs:
	Advertising and sales promotion expenses are expensed as incurred.
	Research and development and Investment and Advances to Non-Consolidated Entities:
	In accordance with ASC 730-10-25 “Accounting for Research and Development Costs,” all research and development (“R&D”) costs are expensed when they are incurred, unless they are reimbursed under specific contracts. Assets used in R&D activity, such as machinery, equipment, facilities and patents that have alternative future use either in R&D activities or otherwise are capitalized. In connection with investments and advances in development-stage technology entities in which the company owns or controls less than a 50% voting interest, (see Note 4) where repayment from such entity is based on the results of the research and development having future economic benefit, the investment and advances are accounted for as costs incurred by the Company as research and development in accordance with ASC 730-20-25 “Research and Development Arrangements”.
	Income taxes:
	The Company accounts for income taxes in accordance with ASC 740-10-25, “Accounting for Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against deferred tax assets to the extent that it is more likely than not that the deferred tax assets will not be realized.
	Comprehensive Income (Loss):
	ASC 220-10-25, “Accounting for Comprehensive Income,” establishes standards for reporting and disclosure of comprehensive income and its components (including revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The items of other comprehensive income that are typically required to be disclosed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. Accumulated other comprehensive loss, at June 30, 2014 is $91,616.
	Translation of Foreign Currencies:
	The U.S. dollar is the functional currency for all of the Company’s businesses, except its operations in Hungary. Foreign currency denominated assets and liabilities for this unit is translated into U.S. dollars based on exchange rates prevailing at the end of each period presented, and revenues and expenses are translated at average exchange rates during the period presented. The effects of foreign exchange gains and losses arising from these translations of assets and liabilities are included as a component of equity, under other comprehensive income.
	Loss per Share:
	Under ASC 260-10-45, “Earnings Per Share”, basic loss per common share is computed by dividing the loss applicable to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted loss per common share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Accordingly, the weighted average number of common shares outstanding for the periods ended June 30, 2014 and December 31, 2013, respectively, is the same for purposes of computing both basic and diluted net income per share for such years. For the periods ended June 30, 2014 and December 31, 2013, all potential shares of common stock were excluded from diluted EPS as their effect would be anti-dilutive.
	The Company currently has the following convertible securities issued and outstanding:
		-	1,000,000 Shares of our Series B Preferred Stock used for the Genetic Immunity acquisition, convertible into 40 shares of common stock per each Series B preferred, or a total of 40,000,000 common shares on a fully converted basis, beginning on January 1, 2014.
		-	1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis.
		-	1,000,000 Shares of our Series D Preferred Stock convertible into 2 shares of common stock per each Series D preferred, or a total of 2,000,000 common stock on a fully converted basis.
		-	450,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 4,500,000 common stock on a fully converted basis.
		-	And we have one Warrant outstanding, convertible into 3,977,386 Shares of our common stock on a fully converted basis.
	Business Segment:
	ASC 280-10-45, “Disclosures About Segments of an Enterprise and Related Information,” establishes standards for the way public enterprises report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim financial statements regarding products and services, geographical areas and major customers. The Company has determined that under ASC 280-10-45, there are no operating segments since substantially all business operations, assets and liabilities are in Hungarian geographic segment.
	Share-Based Payments:
	In accordance with ASC 718-10 “Share-Based Payment” all forms of share-based payment (“SBP”) awards including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. As the Company did not issue any employee SBP prior to September 30, 2007, there is no compensation cost recognized in the accompanied consolidated financial statements.
	The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 505-50, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. Non-employee stock-based compensation charges are amortized over the vesting period or period of performance of the services.
	Recent Accounting Pronouncements:
	In June 2014, the FASB issued Accounting Standards Update 2014-10 Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The objective of the amendments in this Update is to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements for development stage entities. The amendments in this Update remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with providing that information The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014, early adaptation is permitted.
	There were various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Other_Receivables

Other Receivables	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Other Receivables	'
	NOTE 3 - OTHER RECEIVABLES
		June 30,		December 31,
		2014		2013
	Taxes reclaimable	$	53,154	$	10,940
	Advances given		134,820		178,075
	Other		213		28,404
	Total	$	188,187	$	217,419
	Given advances contain advances to lawyers on the legal case of Genetic Immunity on its legal case in progress. The Company accounted for impairment on advances given in the amount of $88,117 during 2013.

Research_And_Development_RD

Research And Development (R&D)	6 Months Ended
	Jun. 30, 2014
Research and Development [Abstract]	'
Research and Development ("R&D")	'
	NOTE 4 - RESEARCH AND DEVELOPMENT (“R&D”)
	In August, 2008, the Company entered into an agreement with a Hungarian individual to establish FireLESS Kft (FireLESS). FireLESS’s business is focused on acquiring the appropriate licenses and certificates to internationally market FireSAFE and will work with local and international fire agencies to test and establish usability baselines for FireSAFE. The Company is a minority shareholder in FireLESS with 30% voting rights, which operates under independent management.
	In August, 2007, the Company entered into an agreement with two Hungarian individuals to establish In4 Kft (“in4). in4’s business is focused on software development and information technology purposes. Originally the Company was a minority shareholder in in4 with 30% voting rights. In4 Ltd. operates under independent management.
	In August, 2007, the Company also entered into a loan commitment agreement with in4. According to the agreement the Company has committed a loan of approximately $271,000 to in4. The loan amount has been provided by May 31, 2009. In November of 2008 the Company transferred to in4 the entire loan amount, upon which the Company elected to covert the loan into an additional 10% equity in in4. As of January 15, 2009 the Company maintains a minority 40% equity in in4 Ltd. Since capitalization of the loan to equity, as of December 31, 2009 the Company has provided an additional $310,000 loan to in4. During 2010 a new investor entered in4 Ltd, and the share of the Company decreased to 38.5%.
	Since the repayment of loans, advances and other investment is contingent on the results of the R&D of iGlue having future economic benefit, management has expensed the Company's investment in in4 and in FireLESS of approximately $5,000 and $900, respectively, and loans to in4 of approximately $310,000 as R&D in the accompanying condensed consolidated statements of operations, in accordance with ASC 730-10-25 "Research and Development Arrangements".

Intangibles_And_Fixed_Assets

Intangibles And Fixed Assets	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Intangibles and Fixed Assets	'
	NOTE 5 - INTANGIBLES AND FIXED ASSETS
	Intangibles and Net property and equipment consisted of the followings at June 30, 2014 and December 31, 2013:
		Intangibles			Machinery and other equipments			Vehicles			Total Net property and equipment
	Gross book value
	at December 31, 2012		30,115,115			599,765			319,833			919,598
	Corrections		480,491			376,769						376,769
	Additions		11,329			1,471			—			1,471
	Disposals		—			(324,837	)		—			(324,837	)
	Change in FX rates		5,251			24,266			7,948			32,214
	at December 31, 2013		30,612,186			677,434			327,781			1,005,215
	Additions		—			—			—			—
	Disposals		—			—			—			—
	Change in FX rates		(11,317	)		(39,140	)		(16,276	)		(55,416	)
	at June 30, 2014		30,600,869			638,294			311,505			949,799
	Accumulated depreciation and amortization
	at December 31, 2012		22,274			172,722			243,707			416,429
	Corrections		480,491			376,770						376,770
	Additions		50,914			79,744			18,489			98,233
	Disposals		—			(95,121	)		—			(95,121	)
	Change in FX rates		3,126			13,654			6,056			19,710
	at December 31, 2013		556,805			547,769			268,252			816,021
	Additions		26,465			29,968			—			29,968
	Disposals		—			—			—			—
	Change in FX rates		(11,751	)		(30,199	)		(13,320	)		(43,519	)
	at June 30, 2014		571,519			547,538			254,932			802,470
	Net book values at
	December 31, 2012		30,092,841			427,043			76,126			503,169
	December 31, 2013		30,055,381			129,665			59,529			189,194
	June 30, 2014		30,029,350			90,756			56,573			147,329
	The net book value of fixed assets under capital lease amount to $57,573 and $59,529 at June 30, 2014 and at December 31, 2013, respectively.
	The Company maintains a significant patent portfolio to protect our intellectual property. |As appropriate we will ocntinue to apply for additional patent protection as we develop our product candidate pipeline.
	During the acquisition of Genetic Immunity, the Company has received the valuation of the patents from an independent valuation company. According to the valuation, the Company entered the acquired intangibles to the consolidated balance sheet. The acquired intangibles have indefinite useful life and annual impairment test is carried out on a discounted cash flow basis. According to the latest valuation carried out at the end of December 2013, no impairment losses were to be recognized.

Note_Payable

Note Payable	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Note Payable	'
	NOTE 6 - NOTE PAYABLE
	Mary Passalaqua
	On October 20, 2011 the Company was presented with an Amended Convertible Promissory Note by Mary Passalaqua. In the revised agreement Ms. Passalaqua requested that the outstanding portion of the Promissory Note be paid in shares in such quantity that will satisfy the debt of $125,000 owned. As second step in this conversion process Mary Passalaqua requested the conversion of $20,000 dollars into shares of common stock. To satisfy this request the Company instructed its transfer agent to issue Mary Passalaqua 3,500,000 shares of common. Upon conversion of the $20,000 outstanding Promissory Note balance will be $105,000 plus accrued interest.
	On August 5, 2011 the company was presented with an Amended Convertible Promissory Note by Mary Passalaqua. In the revised agreement Ms. Passalaqua requested that the outstanding portion of the Promissory Note be paid in shares in such quantity that will satisfy the debt of $195,000 owned. As first step in this conversion process Mary Passalaqua requested the conversion of $70,000 dollars into shares of common stock. To satisfy this request the Company instructed its transfer agent to issue Mary Passalaqua 2,400,000 shares of common. Upon conversion of the $70,000 outstanding Promissory Note balance will be $125,000 plus accrued interest.
	On April 10, 2007, in connection with reverse merger (See Note 1), the Company assumed a note payable of $250,000 to a former stockholder, Mary Passalaqua originally with one year maturity at April 5, 2008. The note has been expanded by one year to April 5, 2009 with the same conditions. As such note payable was issued immediately prior to the reverse merger, such issuance was recorded as additional compensation by the Company prior to the reverse merger. Accordingly, such compensation is reflected in the accompanying consolidated balance sheet as the accumulated deficit of the Company, and will not be reflected in the Statement of operations, as such compensation expense was structured as an expense prior to the recapitalization.
	In November, 2008 the Company settled $35,000 from the outstanding liability, and in May of 2009 the Company settled another $20,000 from the liability. The note payable bears interest at the prime rate (3.25% at June 30, 2014). Interest expense in connection with such note amounted to $54,123 and $52,417 for the periods ended at June 30, 2014 and at December 31, 2013, respectively, and was accrued and included in accounts payable and accrued liabilities in the accompanying consolidated balance sheet.
	Infinite Funding
	On July 19, 2011 the Company entered into a Promissory Note with Infinite Funding, Inc whereby Infinite Funding provided $49,000 dollars in loans to the Company. The Note bears interest at 12% per annum.
	On March 16, 2011 the Company entered into a Convertible Promissory Note with Infinite Funding LLC whereby Infinite Funding provided $76,000 dollars in loans to the Company. The note bears interest at 10%, is due December 5, 2011, and is convertible into shares of common stock at a conversion price of $0.05. On December 4, 2011 the Company received an extension to this note to December 31, 2012. On September 30, 2012, the loan was converted into 1,900,000 common stocks at a conversion price of $0.04 per share.

Capital_Leases_Payable

Capital Leases Payable	6 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Capital Leases Payable	'
	NOTE 7 - CAPITAL LEASES PAYABLE
	In August, 2007, the Company entered into capital lease agreements on 3 vehicles for management purposes. The maturity of the lease is 60 months and is denominated in CHF. Installments and interest is due on a monthly basis. In December, 2007, the Company entered into additional capital lease agreements on 2 vehicles for management purposes. The maturity of the lease is 72 months and is denominated in CHF. Installments and interest is due on a monthly basis.
	In December 2008, the Company settled the capital lease agreements on 2 vehicles and replaced them with new agreements for additional 2 vehicles, totaling 5 capital lease agreements at December 31, 2008. The maturity of the new leases varies from 60 to 72 months and are denominated in EUR and CHF. Installments and interests are due on a monthly basis.
	In September 2009, the Company closed a capital lease agreement for one vehicle. The related asset has been sold.
	The following is a schedule by years of future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of June 30, 2014:
	For the period ending June 30, 2014	Amounts
	2014		49,867
	2015		23,058
	Total minimum lease payments		72,925
	Less: amounts representing interest		3,479
	Present value of net minimum lease payments		69,446
	Less: current portion		69,446
	Long term liability	$	—

Stockholders_Equity

Stockholders Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders Equity	'
	NOTE 8 - STOCKHOLDERS’ EQUITY
	On October 2, 2012 the Company acquired Genetic Immunity, Inc., a US corporation domiciled in the state of Delaware. Genetic Immunity is an immunotherapeutic vaccine company whose lead product candidate DermaVir has passed Phase II clinical trials.
	Through the acquisitions Genetic Immunity became 100% wholly owned subsidiary. The acquisition was completed for 1,000,000 shares of Series B Preferred stock, convertible into 40 million shares of common stock beginning on January 1, 2014.
	On October 26, 2011 the Company entered into an equity exchange agreement with each of Messrs. Viktor Rozsnyay and Daniel Kun, Jr. Mr. Rozsnyay is President, CEO and Chairman of the Board of Directors of the Company and Mr. Kun is its Vice-President. Each Agreement is identical and provides in summary form as follows: each of Messrs. Rozsnyay and Kun will deliver twelve million (12,000,000) shares of their shares of common stock of the Company to the Company for cancellation immediately. The Exchange Shares so delivered were returned to the treasury of the Company as unauthorized shares of common stock to be available for subsequent issuance. In return for the surrender of the Exchange Shares, the Company issued and deliver two million (2,000,000) restricted shares of a new class of Series A Preferred shares, 1,000,000 shares each to Mr. Rozsnyay and Mr. Kun.
	Private placements
	On May 28, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 200,000 shares of its Series E Preferred Stock to two unaffiliated private investors for aggregate proceeds of $100,000.
	On April 28, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 100,000 shares of its Series C Preferred Stock to one unaffiliated private investor for aggregate proceeds of $27,949.
	On April 7, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 50,000 shares of its Series E Preferred Stock to one unaffiliated private investor for aggregate proceeds of $50,000.
	On February 19, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 200,000 shares of its Series E Preferred Stock to two unaffiliated private investors for aggregate proceeds of $200,000. The holders of Series E Preferred Stock are entitled to receive dividends equal to the amount that would be received if each one share of Series E Preferred stock was fully converted into twelve and one half shares of the common stock. Each one share of the Series E Preferred has voting rights equal to five votes of common Stock. Each share of Series E Preferred stock is convertible into 10 shares of common stock.
	On November 1, 2013, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 1,000,000 shares of its Series D preferred stock to one affiliated private investor, Peter Boros, Director of the company, for aggregate proceeds of $337,653. This amount was previously provided to the company by Mr. Boros as a loan, and on November 1 Mr. Boros elected to convert this loan into aforementioned preferred stock. The Series D preferred stock is convertible into 2,000,000 shares of common stock on a fully converted basis. No special redemption rights.
	On October 17, 2013, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 250,000 shares of its Series C Preferred Stock to one unaffiliated private investors for aggregate proceeds of $75,000.
	On September 26, 2013, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 650,000 shares of its Series C Preferred Stock to two unaffiliated private investors for aggregate proceeds of $195,000.
	On September 25, 2013, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 1,000,000 shares of its common stock to one unaffiliated private investors for aggregate proceeds of $80,000.
	Series C Preferred Stocks can be converted with a completed form of conversion notice into 20 shares of common stock. The holders of Series C Preferred shall be entitled to receive dividends on a fully converted basis. Each one share of Series C Preferred shall be entitled to the dividend granted to each one share of common stock multiplied by twenty. Dividends on Series C Preferred must be delivered and paid to the holders not later than five business days after each specified payment date of the dividend.
	On May 9, 2013, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 100,000 shares of its common stock at $0.035 per share to an unaffiliated private investor for aggregate proceeds of $3,500.
	On April 3, 2013, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 1,400,000 shares of its common stock at $0.035 per share to an unaffiliated private investor for aggregate proceeds of $49,000.
	On June 13, 2012, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 42,200 shares of its common stock at $0.3 per share to an unaffiliated private investor for aggregate proceeds of $12,658.
	During the first half of 2012, the Company received stock advance from an unaffiliated private investor for aggregate proceeds of $67,153.
	On November 14, 2011, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 27,700 shares of its common stock at $0.16 per share to an unaffiliated private investor for aggregate proceeds of $4,432.
	On September 2, 2011, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 1,727,013 shares of its common stock at $0.16 per share to two unaffiliated private investors for aggregate proceeds of $276,322.
	On August 29, 2011, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 17,825 shares of its common stock at $0.12 per share to one unaffiliated private investor for aggregate proceeds of $2,137.
	During the second quarter of 2011, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 196,489 shares of its common stock at $0.29 for aggregate proceeds of $56,983.
	During the third quarter of 2010, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 70,000 shares of its common stock at $0.50 for aggregate proceeds of $35,000.
	During the first half of 2010, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 1,470,000 shares of its common stock at $0.10 for aggregate proceeds of $147,000, and sold 62,500 shares of its common stock at $0.08 for proceeds of $5,000.
	In February 2010, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 65,000 shares of its common stock at $0.12 for aggregate proceeds of $7,701.
	In November 2009, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 175,000 shares of its common stock at $0.16 and 111,110 shares of its common stock at $0.20 per share for aggregate proceeds of $50,222.
	In October 2008, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 2,500,000 shares of its common stock at $0.4 per share for aggregate proceeds of $1,000,000.
	In February of 2008, shares of common stock of the Company have been approved by FINRA for quotation and trading on the Over The Counter Bulletin Board (OTCBB) under the ticker symbol PWRV. Trading commenced in the Company’s securities on the OTCBB beginning on February 21, 2008.
	In January 2008, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 32,500 shares of its common stock at $3.25 per share for aggregate proceeds of $105,625.
	In October 2007, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 104,000 shares of its common stock at $2.50 per share for aggregate proceeds of $260,000. The Company also entered into a Registration Rights Agreement, pursuant to which it agreed that as soon as practicable from the Offering Termination Date, as defined in the Registration Rights Agreement, it would file a registration statement with the SEC covering the resale of the shares of the Company’s common stock that are issuable pursuant to this private placement. There are no stipulated damages outlined in the Registration Rights Agreement for failure to file within the agreed upon time frame. Under such agreement, the holder is entitled to exercise all rights granted by law, including recovery of damages under this agreement.
	The Company filed Form SB-2 a registration statement with SEC on November 14, 2007, which was approved on January 30, 2008.
	Consulting agreements
	During November of 2012, the Company entered into agreements with four unaffiliated professionals for one year business consulting services. According to the agreement the professionals provide consulting and rental services to the Company for 12 months. In connection with these services, the Company issued to them 1,930,000 shares of the Company’s common stock. These share issuances were recorded at the fair value of contracting date which is the market price on the commitment date $0.06 and $0.19 per share in the total amount of $180,170 and the related expense was recorded under general administration.
	On April 11, 2012 the Company entered into a Consultation Services agreement with Stockvest for IR services and issued a total of 135,000 shares. As of May 17, 2012 this agreement has been terminated.
	During October 2011, the Company entered into agreements with three unaffiliated professionals for one year business consulting services. According to the agreement the professionals provide consulting services to the Company for 12 months. In connection with these services, the Company issued to them 640,000 shares of the Company’s common stock. These share issuances were recorded at the fair value of contracting date which is the market price on the commitment date $0.11 and $0.09 per share in the total amount of $61,200 and the related expense was recorded under general administration.
	On September 27, 2011, the Company entered into agreements with two unaffiliated professionals for one year business consulting services. According to the agreement the professionals provide consulting services to the Company for 12 months. In connection with these services, the Company issued to them 100,000 shares of the Company’s common stock. These share issuances were recorded at the fair value of contracting date which is the market price on the commitment date $0.14 per share in the total amount of $14,000 and the related expense was recorded under general administration.
	During April and May of 2011, the Company entered into agreements with five unaffiliated professionals for one year business consulting services. According to the agreement the professionals provide consulting services to the Company for 12 months. In connection with these services, the Company issued to them 505,000 shares of the Company’s common stock.
	These share issuances were recorded at the fair value of contracting date which is the market price on the commitment date, ranging from $0.34 to $0.48 per share in the total amount of $190,900 and the related expense was recorded under general administration.
	On February 7, 2011 the Company entered into a one year business consultation agreement with an unaffiliated person who is to provide general business development and incubation consultation. In exchange for his services the Company issued a onetime payment of 215,000 shares of our common stock, which vested immediately. These share issuances were recorded at $0.3 per share in the total amount of $64,500 and the related expense was recorded under general administration.
	On February 9, 2011 the Company entered into a one year business consultation agreement with an unaffiliated person who is to provide services in term of potential business opportunities in Poland. In exchange for his services we issued a onetime payment of 435,000 shares of our common stock, which vested immediately. These share issuances were recorded at $0.24 per share in the total amount of $104,400 and the related expense was recorded under general administration.
	On February 24, 2011 the Company entered into a one year business consultation agreement with an unaffiliated person who is to provide general business development and incubation consultation. In exchange for his services we issued a onetime payment of 75,000 shares of our common stock, which vested immediately. These share issuances were recorded at $0.3 per share in the total amount of $22,500 and the related expense was recorded under general administration.
	The consulting agreements are entered for a 12 months period. According to the agreements the consultants will provide general business consulting services. As consideration for such services, the Company issued an aggregate of 1,970,000 shares of the Company’s common stock. These share issuances were recorded at the fair value of commitment date in the total amount of $457,888 in accordance with measurement date principles prescribed under ASC 505-50 and ASC 718-10. The Company is amortizing the fair value of the shares over the term of the agreement to stock-based compensation expense, which amounted to zero for the period ended June 30, 2014 and 2013, respectively and $316,098 for the period from April 26, 2006 (date of inception) to June 30, 2014, in accordance with ASC 505-50 and ASC 718-10.
	During the October and November 2010, the Company entered into agreements with several unaffiliated professionals for consulting services. According to the agreement the professionals provide consulting services to the Company in 2010. In connection with these services, the Company issued to them 874,000 shares of the Company’s common stock. These share issuances were recorded at $0.5 per share in the total amount of $437,000 and the related expense was recorded under general administration.
	In September 2010, the Company entered into an agreement with four unaffiliated professionals for consulting services. According to the agreement the professionals provided consulting services to the Company in 2010. In connection with these services, the Company issued to them 153,000 shares of the Company’s common stock. These share issuances were recorded at $0.5 per share in the total amount of $76,500 and the related expense was recorded under general administration.
	The consulting agreements are entered for a 12 months period. According to the agreements the consultants will provide general business consulting services. As consideration for such services, the Company issued an aggregate of 1,027,000 shares of the Company’s common stock. These share issuances were recorded at the fair value of commitment date ($0.5 per share) in the total amount of $513,500 in accordance with measurement date principles prescribed under ASC 505-50 and ASC 718-10. The Company is amortizing the fair value of the shares over the term of the agreement to stock-based compensation expense, which amounted to $0 and $312,972 for the periods ended June 30, 2014 and December 31, 2013, respectively and $513,500 for the period from April 26, 2006 (date of inception) to June 30, 2014, in accordance with ASC 505-50 and ASC 718-10.
	In June 2010, the Company entered into an agreement with two unaffiliated professionals for consulting services. According to the agreement the professionals provided consulting services to the Company in 2010. In connection with these services, the Company issued to them 20,000 shares of the Company’s common stock. These share issuances were recorded at $0.1 per share in the total amount of $2,000 and the related expense was recorded under general administration.
	In April 2009, the Company entered into an agreement with two unaffiliated professionals for consulting services. According to the agreement the professionals provided consulting services to the Company in 2009. In connection with these services, the Company issued to them 250,000 shares of the Company’s common stock. These share issuances were recorded at $0.4 per share in the total amount of $100,000 and the related expense was recorded under general administration.
	In June 2007, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 2,250,000 shares of its common stocks at $0.34 per share for a total subscription receivable of $765,000. The Company also entered into a Registration Rights Agreement, pursuant to which it agreed that as soon as practicable from the Offering Termination Date, as defined in the Registration Rights Agreement, it would file a registration statement with the SEC covering the resale of the shares of the Company’s common stock that are issuable pursuant to this private placement. There are no stipulated damages outlined in the Registration Rights Agreement for failure to file within the agreed upon time frame. Under such agreement, the holder is entitled to exercise all rights granted by law, including recovery of damages under this agreement. In June 2007, the Company entered into five consulting agreements with five consultants for 12 to 24 month periods. According to the agreements the consultants will provide general business consulting services. As consideration for such services, the Company issued an aggregate of 1,375,000 shares of the Company’s common stock. These share issuances were recorded at $0.34 per share in the total amount of $467,501 in accordance with measurement date principles prescribed under ASC 505-50 and ASC 718-10. The Company is amortizing the fair value of the shares over the term of the agreement to stock-based compensation expense, which amounted to $0 for the period ended June 30, 2014 and December 31, 2013, respectively and $467,501 for the period from April 26, 2006 (date of inception) to June 30, 2014, in accordance with ASC 505-50 and ASC 718-10.
	In April 2007, the Company entered into an agreement with two professionals for legal services. According to the agreement the professionals provided legal services to the Company in 2007. In connection with these services, the Company issued to them 500,000 shares of the Company’s common stock. These share issuances were recorded at $0.34 per share in the total amount of $170,000 and the related expense was recorded under general administration.
	In connection with the ITA in 2007 (See Note 4), the Company issued 100,000 shares of the Company’s common stock to the Inventors. These shares issuance were recorded at fair value of $0.34 per share in the total amount of $34,000. The cost of the related invention was recorded as research and development expense.
	Other agreements
	On October 8, 2008, Power of the Dream Ventures, Inc. (the “Company”) entered into a Standby Equity Distribution Agreement (the “Standby Equity Distribution Agreement”) with YA Global Investments, L.P. (the “Investor”). Pursuant to the terms of the Standby Equity Distribution Agreement, the Company (a) agreed to issue and sell to the Investor up to $5,000,000 of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) in tranches of equity, based upon a 7% discount to the market price of the Common Stock, calculated over the five trading days following notice by the Company of an election to sell shares; and (b) issued to the Investor a warrant (the “Warrant”) to purchase 4,027,386 shares of Common Stock at the exercise price per share of $0.29. The Warrant is not part of the commitment shares issued by the company to the investor.
	The investor must purchase the shares underlying the Warrant. The Warrant price was determined based upon the highest Bid price on the day of the closing of the agreement. The YA Global is required to exercise the warrant upon notice by PDV of an election to have the warrants exercised at a fix price of $0.29 per common stock.
	In connection with the Standby Equity Distribution Agreement, the Company entered into a Registration Rights Agreement with the Investor (the “Registration Rights Agreement”) pursuant to which the Company agreed to register for resale the shares of Common Stock that may be purchased by the Investor pursuant to the Standby Equity Distribution Agreement, the shares of Common Stock issuable upon exercise of the Warrant and 2,000,000 shares of Common Stock (the “Commitment Shares”) issued to the Investor as a commitment fee pursuant to the terms of the Standby Equity Distribution Agreement. The 2,000,000 shares issued as a commitment fee were valued at $0.4 per share or $800,000 based on the fair value at issuance date. The $800,000 commitment fee has been debited against additional paid in capital in accordance with the provisions of Staff Accounting Bulletin Topic 5A .
	On September 24, 2010 the Company notified YA Global Investments in writing of its intention to terminate the Standby Equity Distribution Agreement (SEDA).
	In response to this letter YA Global informed the company in a letter dated October 5, 2010 that the SEDA agreement will terminate on or about October 15, 2010. YA Global also informed the company that even though the SEDA agreement is terminated its associated Warrant to purchase 4,027,386 shares of common stock remains in effect until it expires on October 8, 2013.
	On October 18, 2010 the company received notice from YA global for the exercise of 50,000 warrant shares on a cashless basis. This cashless exercise resulted in the issuance of 3,226 shares of Common stock to YA Global. Following this exercise YA Global has 3,977,386 warrant shares available for purchase.
	On September 10, 2012 YA Global notifed the company that according to the terms of the Warrant Agreement there should have been a proportional reduction in the Warrant’s exercise price to the the price of a private placement that was completed at a lower price than the $0.29 exercise price. YA Global and the company have agreed to modify the Warrant exercise price from the original $0.29 cents to $0.10 cents.
	At the same time YA Global also notified the company of their intention to sell the Warrant in a private transaction to an unaffiliated accredited investor. This transaction was contemplated on September 10, 2012. The new owner, Bluestar Consulting, now has the right to acquire, on or before October 8, 2013, 3,977,386 share of common stock at a per share exercise price of $0.10. The terms of the warrants are such that the exercise price was lowered due to a subsequent round of financing, from $0.29 per share to the price the subsequent investors paid, $0.10 per share. This down round protection feature causes the warrant to fail the criteria in ASC 815-40-15-7 (EITF 07-5) which would permit them to be classified as equity.  Consequently, the warrants are recorded at fair value and classified as liabilities and marked to fair value each period. The warrant is extended to October 8, 2018.
	The fair value of the liability using Black-Scholes valuation at June 30, 2014 is $91,480, which is classified at short term liabilities. The fair value of the liability is established as a Level 3 fair value measurement. The following table shows the movement in fair value along with the change of warrant conditions:
	30-Jun-14	Book value			Fair value
	Financial liabilities
	Liabilities measured at fair value		91,480			91,480
31-Dec-13	Book value			Fair value
Financial liabilities
Liabilities measured at fair value		87,502			87,502
Fair value of warrant per share		30-Jun-14			31-Dec-13
Per share		$	0.037		$	0.022
The inputs used in fair value estimation are:
current share price at June 30, 2014:	$	0.0701
exercise price	$	0.1
expected time to expiry (years):		4.25
risk free rate		3.25 (FED prime rate)
expected dividend yield:		0
volatility:		50	%
The change in the amount of warrant liability is accounted as other expense.
On May 17, 2008 the Company entered into an agreement with Wakabayashi Fund LLC in order to arrange financing for working capital as an intermediary. Wakabayashi Fund LLC provided capital funding services including serving as an investment banking liaison and acted as capital consultant for a six month period. The Company issued 111,111 shares of restricted common stock upfront at $1.35 per share, the market price of the stock on the commitment date of the agreement. Additionally, the Company agreed to pay for the capital funding services 7% success fee. These share issuances were recorded at $1.35 per share in the total amount of $150,000 in accordance with measurement date principles prescribed under ASC 505-50. The Company is amortizing the fair value of the shares in general and administration expenses over the term of the agreement to stock-based compensation expense, which amounted to $0 for the period ended June 30, 2014 and December 31, 2013 and $150,000 for the period from April 26, 2006 (date of inception) to June 30, 2014, in accordance with ASC 505-50. As of November 17, 2008 this agreement has been terminated without any funds raised.
On April 18, 2008 the Company entered an agreement with RedChip Companies Inc. and Partner Media4Equity Inc. for an investor relationship program for a period of 12 months. The Company secured and delivered 306,570 restricted common shares with a market price of $0.70 for a 12 months period in connection with RedChip investor relationship services. The compensation for Media4Equity services was the delivery of 1,500,000 restricted common shares. These share issuances were recorded at $0.75 per share, the market price of the stock on the commitment date of the agreement, for a total amount of $1,125,000 in accordance with measurement date principles prescribed under ASC 505-50. The Company is amortizing the fair value of the shares in general and administration expenses over the term of the agreement to stock-based compensation expense, which amounted to $0 for the periods ended June 30, 2014 and December 31, 2013, respectively and $1,339,599 for the period from April 26, 2006 (date of inception) to June 30, 2014, in accordance with ASC 505-50.
Stock based compensations
On January 1, 2011, the Company entered into a restricted stock agreement with Ildiko Rozsa, who is to serve as the Chief Financial Officer of the Company. As part of the agreement Ms. Rozsa was granted 100,000 shares of the Company’s restricted common stock of which 25,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Rozsa is employed by the Company.
On January 1, 2011, the Company entered into a restricted stock agreement with Szilvia Toth, the Chief Accounting Officer of the Company. As part of the agreement Ms. Toth was granted 100,000 shares of restricted common stock, of which 25,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Toth is employed by the Company.
On January 1, 2011, the Company entered into a restricted stock agreement with Imre Eotvos, the Technology Assistant of the Company. As part of the agreement Mr. Eotvos was granted 120,000 shares of restricted common stock, which will vest on equal installments of 30,000 shares quarterly, at the end of each quarter, so long as Mr. Eotvos is employed by the Company.
On January 1, 2011, the Company entered into a restricted stock agreement with Daniel Kun, Jr., who is to serve as Secretary and Vice President of the company on a going forward basis. As part of the agreement Mr. Kun was granted 120,000 shares of restricted common stock, which will vest on equal installments of 30,000 shares quarterly, at the end of each quarter, so long as Mr. Kun is employed by the Company.
On January 1, 2011, the Company entered into a restricted stock agreement with Gene Guhne, who is to serve as Director of the company on a going forward basis. As part of the agreement Mr. Guhne was granted 100,000 shares of restricted common stock, which will vest on equal installments of 25,000 shares quarterly, at the end of each quarter, so long as Mr. Guhne is employed by the Company.
As consideration for the above services, the Company issued an aggregate of 540,000 shares of the Company’s common stock. These share issuances were recorded at $0.15 per share in the total amount of $81,000 in accordance with measurement date principles prescribed under FAS 123 (R).
During the second quarter of 2010, the Company entered into a restricted stock agreement with Ildiko Rozsa, who is to serve as the Chief Financial Officer of the Company. As part of the agreement Ms. Rozsa was granted 100,000 shares of the Company’s restricted common stock of which 25,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Rozsa is employed by the Company.
During the second quarter of 2010, the Company entered into a restricted stock agreement with Szilvia Toth, the Chief Accounting Officer of the Company. As part of the agreement Ms. Toth was granted 100,000 shares of restricted common stock, of which 25,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Toth is employed by the Company.
During the second quarter of 2010, the Company entered into a restricted stock agreement with Imre Eotvos, the Technology Assistant of the Company. As part of the agreement Mr. Eotvos was granted 120,000 shares of restricted common stock, which will vest on equal installments of 30,000 shares quarterly, at the end of each quarter, so long as Mr. Eotvos is employed by the Company.
During the second quarter of 2010, the Company entered into a restricted stock agreement with Daniel Kun, Jr., who is to serve as Secretary and Vice President of the company on a going forward basis. As part of the agreement Mr. Kun was granted 120,000 shares of restricted common stock, which will vest on equal installments of 30,000 shares quarterly, at the end of each quarter, so long as Mr. Kun is employed by the Company.
During the second quarter of 2010, the Company entered into a restricted stock agreement with Gene Guhne, who is to serve as Director of the company on a going forward basis. As part of the agreement Mr. Guhne was granted 100,000 shares of restricted common stock, which will vest on equal installments of 25,000 shares quarterly, at the end of each quarter, so long as Mr. Guhne is employed by the Company.
As consideration for the above services, the Company issued an aggregate of 540,000 shares of the Company’s common stock. These share issuances were recorded at $0.1 per share in the total amount of $54,000 in accordance with measurement date principles prescribed under FAS 123 (R).
On February 5, 2009, the Company entered into a restricted stock agreement with Ildiko Rozsa, who is to serve as the Chief Financial Officer of the Company. As part of the agreement Ms. Rozsa was granted 120,000 shares of the Company’s restricted common stock of which 30,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Rozsa is employed by the Company.
On February 5, 2009, the Company entered into a restricted stock agreement with Szilvia Toth, the Chief Accounting Officer of the Company. As part of the agreement Ms. Toth was granted 120,000 shares of restricted common stock, of which 30,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Toth is employed by the Company.
On February 5, 2009, the Company entered into a restricted stock agreement with Mihaly Zala, the Chief Technology Officer of the Company. As part of the agreement Mr. Zala was granted 120,000 shares of restricted common stock, which will vest on equal installments of 30,000 shares quarterly, at the end of each quarter, so long as Mr. Zala is employed by the Company. As of July 15, 2009 Mr. Zala is no longer employed by the Company, therefore 60,000 shares of the 120,000 granted to him were cancelled and returned to the authorized and unissued stock of the company.
On February 5, 2009, the Company entered into a restricted stock agreement with Imre Eotvos, the Technology Assistant of the Company. As part of the agreement Mr. Eotvos was granted 200,000 shares of restricted common stock, which will vest on equal installments of 50,000 shares quarterly, at the end of each quarter, so long as Mr. Eotvos is employed by the Company.
On February 5, 2009, the Company entered into a restricted stock agreement with Daniel Kun, Jr., who is to serve as Secretary and Vice President of the company on a going forward basis. As part of the agreement Mr. Kun was granted 200,000 shares of restricted common stock, which will vest on equal installments of 50,000 shares quarterly, at the end of each quarter, so long as Mr. Kun is employed by the Company.
As consideration for the above services, the Company issued an aggregate of 700,000 shares of the Company’s common stock. These share issuances were recorded at $0.4 per share in the total amount of $280,000 in accordance with measurement date principles prescribed under FAS 123 (R).
On October 24, 2007, the Company entered into a restricted stock agreement with Ildiko Rozsa, who is to serve as the Chief Financial Officer of the Company. As part of the agreement Ms. Rozsa was granted 250,000 shares of the Company’s restricted common stock of which 100,000 shares are vested upon grant and 30,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Rozsa is employed by the Company.
On October 1, 2007, the Company entered into a restricted stock agreement with Szilvia Toth, the Chief Accounting Officer of the Company. As part of the agreement Ms. Toth was granted 100,000 shares of restricted common stock of which 50,000 shares are vested upon grant and 10,000 shares will vest quarterly, at the end of each quarter, so long as Ms. Toth is employed by the Company.
On October 24, 2007, the Company entered into a restricted stock agreement with Mihaly Zala, the Chief Technology Officer of the Company. As part of the agreement Mr. Zala was granted 150,000 shares of restricted common stock, which will vest on equal installments of 30,000 shares quarterly, at the end of each quarter, so long as Mr. Zala is employed by the Company.
On October 24, 2007, the Company entered into a restricted stock agreement with Imre Eotvos, the Technology Assistant of the Company. As part of the agreement Mr. Eotvos was granted 25,000 shares of restricted common stock, which will vest on equal installments of 5,000 shares quarterly, at the end of each quarter, so long as Mr. Eotvos is employed by the Company.
On October 1, 2007, the Company entered into a restricted stock agreement with Sandorne Juhasz, who provides payroll accounting services to the Company on a subcontracting basis. As part of the agreement Ms. Juhasz was granted 11,000 shares of restricted common stock, of which 8,000 is will vest upon grant and 750 shares will vest quarterly, at the end of each quarter, so long as Ms. Juhasz is employed by the Company.
On October 24, 2007, the Company entered into a restricted stock agreement with Daniel Kun, Jr., who is to serve as Secretary and Vice President of the company on a going forward basis. As part of the agreement Mr. Kun was granted 250,000 shares of restricted common stock, which will vest on equal installments of 50,000 shares quarterly, at the end of each quarter, so long as Mr. Kun is employed by the Company.
On October 24, 2007, the Company entered into a restricted stock agreement with Viktor Rozsnyay, who is serving as President and Chief Executive Officer of the Company. As part of the agreement Mr. Rozsnyay was granted 250,000 shares of restricted common stock, which will vest on equal installments of 50,000 shares quarterly, at the end of each quarter, so long as Mr. Rozsnyay is employed by the Company.
As consideration for the above services for the employment of the above 7 persons, the Company issued an aggregate of 1,036,000 shares of the Company’s common stock. These share issuances were recorded at $2.5 per share in the total amount of $2,590,000 in accordance with measurement date principles prescribed under ASC 505-50 and ASC 718-10. The Company is amortizing the fair value of the shares over the term of the agreement to stock-based compensation expense, which amounted to $0 for the period ended June 30, 2014 and December 31, 2013 and $2,590,000 for the period from April 26, 2006 (date of inception) to June 30, 2014, in accordance with ASC 505-50 and ASC 718-10.
Reverse merger
On August 5, 2011 the company was presented with an Amended Convertible Promissory Note by Mary Passalaqua. In the revised agreement Ms. Passalaqua requested that the outstanding portion of the Promissory Note be paid in shares in such quantity that will satisfy the debt of $195,000 owned. As first step in this conversion process Mary Passalaqua requested the conversion of $70,000 dollars into shares of common stock. To satisfy this request the Company instructed its transfer agent to issue Mary Passalaqua 2,400,000 shares of common. On October 20, 2011, Mary Passalaqua requested the conversion of additional $20,000 dollars into shares of common stock. To satisfy this request the Company instructed its transfer agent to issue Mary Passalaqua 3,600,000 shares of common.
On October 20, 2011 the Company was presented with an Amended Convertible Promissory Note by Mary Passalaqua. In the revised agreement Ms. Passalaqua requested that the outstanding portion of the Promissory Note be paid in shares in such quantity that will satisfy the debt of $125,000 owned. As second step in this conversion process Mary Passalaqua requested the conversion of $20,000 dollars into shares of common stock. To satisfy this request the Company instructed its transfer agent to issue Mary Passalaqua 3,500,000 shares of common. Upon conversion of the $20,000 outstanding Promissory Note balance will be $105,000 plus accrued interest.
On April 10, 2007, PDV entered into a reverse merger transaction with Vidatech. In connection with the merger 2,500,000 shares of PDV common stock remained outstanding and PDV issued 33,300,000 shares of its common stock for all the outstanding common stock of Vidatech. As a result of this transaction, the former stockholders of Vidatech became the controlling stockholders of PDV. Accordingly, the reverse merger has been accounted for as a recapitalization of Vidatech.
In May, 2006, the Company entered into a short term loan agreement with its Chief Executive Officer, Viktor Rozsnyay, for approximately $96,100 with a maturity of April 30, 2007. On December 28, 2006 Mr. Rozsnyay elected to convert the loan into equity, which is recorded as additional paid in capital.
In March, 2007, the Company entered into a short term loan agreement with its Chief Financial Officer, Daniel Kun Jr., for approximately $53,735 with a maturity of March 31, 2007. On March 31, 2007 Mr. Kun elected to convert the loan into equity, which is recorded as additional paid in capital.

Accounts_Payable_Accrued_And_O

Accounts Payable, Accrued And Other Liabilities	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable, Accrued and Other Liabilities	'
	NOTE 9 - ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES
		June 30,		December 31,
		2014		2013
	Accounts payable and accrued expenses	$	1,922,716	$	1,868,534
	Interest accruals		2,433,654		2,214,760
	Total	$	4,356,370	$	4,083,294
	In 2007, Genetic Immunity conducted a US$2.0 million convertible debenture bridge in anticipation of a reverse merger which was not consummated due to then current economic and market conditions. The debenture was due August 2009. The US$1.1 million in face value of debentures was purchased by a fund operating under the Small Business Investment Company (“SBIC”) which has since been put into receivership with the U.S. Small Business Administration (the “SBA”). The SBA is expected to execute a forbearance agreement. The remaining US$900,000 of face value of the debenture is held by individuals who are considering whether to sign the forbearance agreement. Conrad Mir, the Company’s Chairman of the Board of Directors, is in dialogue with them. The debenture holders have liens on certain intellectual property of the Company. Because there is significant know how associated with the intellectual property, the involvement of the Company's management team and scientific team is necessary to commercialize the intellectual property. As of the printing of this document, the Company received written consent from the SBA to proceed with the forbearance agreement and is awaiting similar approval from the aforementioned individuals. If said individuals elect to not accept the terms of the forbearance agreement as approved by the Company and the SBA, thus keeping the Company in default on its obligations, there is the potential for litigation by the holders of the debentures.
	In 2013, the Company accounted for the late payment interest for the Bridge loan (18%) which increased the accrued interest liability significantly, along with the interest expenses.

Grants_Received

Grants Received	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Grants Received	'
	NOTE 10 - GRANTS RECEIVED
	During 2007 and 2008, Genetic Immunity gained several government grants from the Hungarian state in order to finance the research and development projects. The grants are payable in arrears to 4 projects of the Company: DERMAVI_, DVCLIN01, FIBERSC2 and WINGS. The Company accrued for the grants received and it is reversed to the income statement along with the occurrence of the related expenses. Grants are payable in accordance with the milestone, not annually. Audited financial statements had to be disclosed to State Office as settlement of each milestone. Theses audits have been performed by the statutory auditor of the Hungarian Subsidiary. WINGS is an EU FP7 international consortium grant financed by the European Union.
	DERMAVI_ is successfully closed in 2009. DVCLIN01 supported the Phase II clinical development of DermaVir. This grant was closed at the end of 2013. FIBERSC2 supports the investigation of DermaVir mechanism of action with novel fiber integrated microscopy. Originally scheduled for completion in February of 2014, this grant has been extended to August of 2014. WINGS supports the development of West Nile Virus vaccine with DermaVir technology. The grant ended in February of 2014, the Company has filed the required closing documents. The Company expects full closure to this grant in Q3 of 2014.

Short_Term_Loan

Short Term Loan	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Short Term Loan	'
	NOTE 11 - SHORT TERM LOANS
		June 30,		December 31,
		2014		2013
	Bridge Loan	$	2,000,000	$	2,000,000
	RIGHT loan		294,333		311,159
	Bryan Sanders loan		30,000		30,000
	Total		2,324,333		2,341,159
	Bridge Loan
	On August 29, 2007, the Company entered into a Bridge Loan agreement as a Senior Secured Convertible Debenture for an amount of $2,000,000. The loan providers are the followings:
	Name	Bridge Amount
	SBIC Investors
	Trident	$	1,100,000
	Non-SBIC Investors
	Andy Browder		25,000
	Proto Investments		250,000
	Ford Sasser		25,000
	Danny Vela		25,000
	Steve Walton		150,000
	Hilton Wilson		25,000
	Will Wilson		250,000
	Rodman & Renshaw		150,000
		$	2,000,000
	The loan bears an annual interest rate of 12%. According to the loan agreement, the Company settles the loan principal on the earlier of August 29, 2009 or consummation of a qualifying transaction other than reverse merger effected by the Company in completion of or in connection with a Public Offering. In case of late payment, the Company is liable to pay 18% late interest fee. The accumulated interest payable, along with the late payment interest is accrued in accrued expenses (see Note 6).
	As of the printing of this document, the US$1.1 million in face value of debentures has been put into receivership with the U.S. SBA. The debenture holders have liens on certain intellectual property of the Company. Because there is significant know how associated with the intellectual property, the involvement of the Company's management team and scientific team is necessary to commercialize the intellectual property.

Other_Expenses

Other Expenses	6 Months Ended
	Jun. 30, 2014
Other Income and Expenses [Abstract]	'
Other Expenses	'
	NOTE 12 - OTHER EXPENSES
	Other expenses include the revaluation of liability for warrants for Bluestar Consulting in the amount of $3,978.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	NOTE 13 - SUBSEQUENT EVENTS
	None.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	NOTE 14 - CONTINGENCIES
	The Company’s wholly-owned subsidiary, Genetic Immunity, has initiated a lawsuit against the National Development Agency of Hungary. In 2009, Genetic Immunity successfully applied for and won an 800 million Hungarian forint (approximately $4,000,000) research grant to conduct dust mite allergy vaccine research. Subsequently, the agency refused to sign the grant and denied payment of funds. The company initiated a lawsuit to request that the court reinstate the contract that resulted in a grant award. On February 13, 2013, an appeals court ruled that the court could not reinstate the contract between Genetic Immunity and the National Development Agency as the contract has been validly in existence since its original execution in 2009. As such Genetic Immunity was ordered to pay 52,500,000 HUF (approximately $250,000) in lawsuit costs. However, simultaneously, the judgment stated that the company is entitled to receive the original grant amount, interest payment and/or damages since the original grant contract is valid. On February 18, 2013, the Company filed a new petition to have the courts establish the damages and awards that Genetic Immunity can receive based on the appeals court’s ruling. The Company is currently seeking 4,800,000,000 HUF (approximately $20 million) for damages sustained. On November 18, 2013, the Company has entered into a six month suspension of said lawsuit, as agreed with the government, in hopes of negotiating an out of court settlement. After the lapse of our six month suspension we once again resumed the trial as the Company could not arrive at an out of court settlement. The Company currently awaits a court date for the trial to continue, but in the mean time is still working towards an out of court settlement and the closing of this law suite.

General_Information_Policies

General Information (Policies)	6 Months Ended
	Jun. 30, 2014
General Information Policies	'
Basis of presentation	'
	Basis of presentation
	The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America for financial information have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading as of and for the period ended June 30, 2014 and for the period from April 26, 2006 (date of inception) to June 30, 2014.
Going Concern and Management's Plan	'
	Going Concern and Management’s Plan
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate the continuation of the Company as a going concern and assume realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses from operations since inception. Management anticipates incurring additional losses in 2014. Further, the Company may incur additional losses thereafter, depending on its ability to generate revenues from the licensing or sale of its technologies and products, or to enter into any or a sufficient number of joint ventures. The Company has minimal revenue to date. There is no assurance that the Company can successfully commercialize any of its technologies and products and realize any revenues therefore. The Company’s technologies and products have never been utilized on a large-scale commercial basis and there is no assurance that any of its technologies or products will receive market acceptance. There is no assurance that the Company can continue to identify and acquire new technologies.
	Since inception through June 30, 2014, the Company had an accumulated deficit of $13,764,235 and net cash used in operations of $3,074,863. However, management of the Company believes that future funding from the private placement of the Company’s common shares will allow them to continue operations and execute its business plan.
	During 2014 and 2013 the Company raised a total of $377,949 and $401,500, respectively through private placements of common and preferred stock. These funds were used to finance operations, to reduce Genetic Immunity debt, and to finance Genetic Immunity’s regulatory process towards a marketing approval application. Additional funds used for these tasks, in the amount of $337,657 were previously provided in the prior years by the director, Peter Boros, who elected in November of 2013 to convert said loan into 1,000,000 shares of our Series D Preferred Stock.
	On March 16, 2011 the Company entered into a Convertible Promissory Note with Infinite Funding LLC whereby Infinite Funding provided $76,000 dollars in loans to the Company. The note bears interest at 10%, is due December 5, 2011, and is convertible into shares of common stock at a conversion price of $0.04. On December 4, 2011 we received an extension to this note to December 31, 2012. The note was converted to 1,900,000 common shares at September 30, 2012.
	On July 19, 2011 the Company entered into a Convertible Promissory Note with Infinite Funding LLC whereby Infinite Funding provided $49,000 dollars in loans to the Company. The note bears interest at 12%.
	Management believes the Company has adequate capital to keep the Company functioning through June 30, 2015. As discussed in contingencies, the Company anticipates receiving funds from the Hungarian state pursuant to the lawsuit it has filed to recover the awards granted to the Company plus damages. Also, additional fund raisings are in progress. However, the Company cannot guarantee that any amount from the lawsuit will be recoverable nor that any fund raising activities will be successful. The need may arise, in the normal course of business, to raise additional capital if we want to accelerate development work, for the acquisition of additional technologies, or to meet unforeseen financial needs. No assurance can be given that the Company can obtain additional working capital, or if obtained, that such funding will not cause substantial dilution to shareholders of the Company. If the Company is unable to raise additional funds, if needed, it may be forced to change or delay its contemplated marketing and business plan. Being a development stage company, the Company is subject to all the risks inherent in the establishment of a new enterprise and the marketing and manufacturing of a new product, many of which risks are beyond the control of the Company. All of the factors discussed above raise substantial doubt about the Company’s ability to continue as a going concern.
	These consolidated financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary as a result of the above uncertainty.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Principals of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of PDV and its wholly-owned Hungarian subsidiary, Vidatech. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates:
	The preparation of the financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect amounts reported herein. Management believes that such estimates, judgments and assumptions are reasonable and appropriate. However, due to the inherent uncertainty involved, actual results may differ from those based upon management’s judgments, estimates and assumptions. Critical accounting policies requiring the use of estimates are depreciation and amortization and share-based payments
Revenue Recognition	'
	Revenue Recognition:
	Sales are recognized when there is evidence of a sales agreement, the delivery of the goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured, generally upon shipment of product to customers and transfer of title under standard commercial terms. Sales are measured based on the net amount billed to a customer. Generally there are no formal customer acceptance requirements or further obligations. Customers do not have a general right of return on products shipped therefore no provisions are made for return.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts:
	Accounts receivable are stated at historical value, which approximates fair value. The Company does not require collateral for accounts receivable. Accounts receivable are reduced by an allowance for amounts that may be uncollectible in the future. This estimated allowance is determined by considering factors such as length of time accounts are past due, historical experience of write offs, and customers’ financial condition.
Inventories	'
	Inventories:
	Inventories are stated at the lower of cost, determined based on weighted average cost or market. Inventories are reduced by an allowance for excess and obsolete inventories based on management’s review of on-hand inventories compared to historical and estimated future sales and usage.
Fixed Assets	'
	Fixed assets:
	Fixed assets are stated at cost or fair value for impaired assets. Depreciation and amortization is computed principally by the straight-line method. Asset amortization charges are recorded for long lived assets. In the related periods, no asset impairment charges were accounted for. Depreciation is recorded commencing the date the assets are placed in service and is calculated using the straight line basis over their estimated useful lives.
	The estimated useful lives of the various classes of long-lived assets are approximately 3-7 years.
Pensions and Other Post-retirement Employee benefits	'
	Pensions and Other Post-retirement Employee benefits:
	In Hungary, pensions are guaranteed and paid by the government or by pension funds, therefore no pensions and other post-retirement employee benefit costs or liabilities are to be calculated and accounted by the Company.
Product Warranty	'
	Product warranty:
	The Company accrues for warranty obligations for products sold based on management estimates, with support from sales, quality and legal functions, of the amount that eventually will be required to settle such obligations. At June 30, 2014, the Company had no warranty obligations in connection with products sold.
Advertising Costs	'
	Advertising costs:
	Advertising and sales promotion expenses are expensed as incurred.
Research and development And Investment and Advances to Non-Consolidated Entities	'
	Research and development and Investment and Advances to Non-Consolidated Entities:
	In accordance with ASC 730-10-25 “Accounting for Research and Development Costs,” all research and development (“R&D”) costs are expensed when they are incurred, unless they are reimbursed under specific contracts. Assets used in R&D activity, such as machinery, equipment, facilities and patents that have alternative future use either in R&D activities or otherwise are capitalized. In connection with investments and advances in development-stage technology entities in which the company owns or controls less than a 50% voting interest, (see Note 4) where repayment from such entity is based on the results of the research and development having future economic benefit, the investment and advances are accounted for as costs incurred by the Company as research and development in accordance with ASC 730-20-25 “Research and Development Arrangements”.
Income Taxes	'
	Income taxes:
	The Company accounts for income taxes in accordance with ASC 740-10-25, “Accounting for Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against deferred tax assets to the extent that it is more likely than not that the deferred tax assets will not be realized.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss):
	ASC 220-10-25, “Accounting for Comprehensive Income,” establishes standards for reporting and disclosure of comprehensive income and its components (including revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The items of other comprehensive income that are typically required to be disclosed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. Accumulated other comprehensive loss, at June 30, 2014 is $91,616.
Translation of Foreign Currencies	'
	Translation of Foreign Currencies:
	The U.S. dollar is the functional currency for all of the Company’s businesses, except its operations in Hungary. Foreign currency denominated assets and liabilities for this unit is translated into U.S. dollars based on exchange rates prevailing at the end of each period presented, and revenues and expenses are translated at average exchange rates during the period presented. The effects of foreign exchange gains and losses arising from these translations of assets and liabilities are included as a component of equity, under other comprehensive income.
Loss Per Share	'
	Loss per Share:
	Under ASC 260-10-45, “Earnings Per Share”, basic loss per common share is computed by dividing the loss applicable to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted loss per common share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Accordingly, the weighted average number of common shares outstanding for the periods ended June 30, 2014 and December 31, 2013, respectively, is the same for purposes of computing both basic and diluted net income per share for such years. For the periods ended June 30, 2014 and December 31, 2013, all potential shares of common stock were excluded from diluted EPS as their effect would be anti-dilutive.
	The Company currently has the following convertible securities issued and outstanding:
		-	1,000,000 Shares of our Series B Preferred Stock used for the Genetic Immunity acquisition, convertible into 40 shares of common stock per each Series B preferred, or a total of 40,000,000 common shares on a fully converted basis, beginning on January 1, 2014.
		-	1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis.
		-	1,000,000 Shares of our Series D Preferred Stock convertible into 2 shares of common stock per each Series D preferred, or a total of 2,000,000 common stock on a fully converted basis.
		-	450,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 4,500,000 common stock on a fully converted basis.
		-	And we have one Warrant outstanding, convertible into 3,977,386 Shares of our common stock on a fully converted basis.
Business Segment	'
	Business Segment:
	ASC 280-10-45, “Disclosures About Segments of an Enterprise and Related Information,” establishes standards for the way public enterprises report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim financial statements regarding products and services, geographical areas and major customers. The Company has determined that under ASC 280-10-45, there are no operating segments since substantially all business operations, assets and liabilities are in Hungarian geographic segment.
Share Based Payments	'
	Share-Based Payments:
	In accordance with ASC 718-10 “Share-Based Payment” all forms of share-based payment (“SBP”) awards including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. As the Company did not issue any employee SBP prior to September 30, 2007, there is no compensation cost recognized in the accompanied consolidated financial statements.
	The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 505-50, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. Non-employee stock-based compensation charges are amortized over the vesting period or period of performance of the services.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements:
	In June 2014, the FASB issued Accounting Standards Update 2014-10 Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The objective of the amendments in this Update is to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements for development stage entities. The amendments in this Update remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with providing that information The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014, early adaptation is permitted.
	There were various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

General_Information_Tables

General Information (Tables)	6 Months Ended
	Jun. 30, 2014
Banking and Thrift [Abstract]	'
Summary of Purchase Price Consideration	'
	A summary of the purchase price consideration and related purchase price allocation are shown below:
	Purchase price (at par value)		$	1
	Fair value adjustment of shares			25,072,621
	Total purchase price			25,073,621
Schedule of Purchase Price Allocation	'
	Purchase price allocation
	Cash	$	357,276
	Inventories		13,843
	Other receivables		306,731
	Intangibles		30,111,909
	Fixed assets		418,483
	Accounts payable and accrued liabilities		(1,893,833	)
	Grants received		(1,677,348	)
	Short term loans to related parties		(154,631	)
	Bridge loan		(2,334,326	)
	Other liabilities		(73,483	)
	Total purchase price		25,074,621

Other_Receivables_Tables

Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Schedule of Other Receivables	'
		June 30,		December 31,
		2014		2013
	Taxes reclaimable	$	53,154	$	10,940
	Advances given		134,820		178,075
	Other		213		28,404
	Total	$	188,187	$	217,419

Intangibles_And_Fixed_Assets_T

Intangibles And Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Intangibles and Fixed Assets	'
	Intangibles and Net property and equipment consisted of the followings at June 30, 2014 and December 31, 2013:
		Intangibles			Machinery and other equipments			Vehicles			Total Net property and equipment
	Gross book value
	at December 31, 2012		30,115,115			599,765			319,833			919,598
	Corrections		480,491			376,769						376,769
	Additions		11,329			1,471			—			1,471
	Disposals		—			(324,837	)		—			(324,837	)
	Change in FX rates		5,251			24,266			7,948			32,214
	at December 31, 2013		30,612,186			677,434			327,781			1,005,215
	Additions		—			—			—			—
	Disposals		—			—			—			—
	Change in FX rates		(11,317	)		(39,140	)		(16,276	)		(55,416	)
	at June 30, 2014		30,600,869			638,294			311,505			949,799
	Accumulated depreciation and amortization
	at December 31, 2012		22,274			172,722			243,707			416,429
	Corrections		480,491			376,770						376,770
	Additions		50,914			79,744			18,489			98,233
	Disposals		—			(95,121	)		—			(95,121	)
	Change in FX rates		3,126			13,654			6,056			19,710
	at December 31, 2013		556,805			547,769			268,252			816,021
	Additions		26,465			29,968			—			29,968
	Disposals		—			—			—			—
	Change in FX rates		(11,751	)		(30,199	)		(13,320	)		(43,519	)
	at June 30, 2014		571,519			547,538			254,932			802,470
	Net book values at
	December 31, 2012		30,092,841			427,043			76,126			503,169
	December 31, 2013		30,055,381			129,665			59,529			189,194
	June 30, 2014		30,029,350			90,756			56,573			147,329

Capital_Leases_Payable_Tables

Capital Leases Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Schedule of Future Minimum Leases Payment	'
	The following is a schedule by years of future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of June 30, 2014:
	For the period ending June 30, 2014	Amounts
	2014		49,867
	2015		23,058
	Total minimum lease payments		72,925
	Less: amounts representing interest		3,479
	Present value of net minimum lease payments		69,446
	Less: current portion		69,446
	Long term liability	$	—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value of Liabilities	'
	The following table shows the movement in fair value along with the change of warrant conditions:
	30-Jun-14	Book value			Fair value
	Financial liabilities
	Liabilities measured at fair value		91,480			91,480
	31-Dec-13	Book value			Fair value
	Financial liabilities
	Liabilities measured at fair value		87,502			87,502
	Fair value of warrant per share		30-Jun-14			31-Dec-13
	Per share		$	0.037		$	0.022
Schedule of Fair Value Estimation	'
	The inputs used in fair value estimation are:
	current share price at June 30, 2014:	$	0.0701
	exercise price	$	0.1
	expected time to expiry (years):		4.25
	risk free rate		3.25 (FED prime rate)
	expected dividend yield:		0
	volatility:		50	%

Accounts_Payable_Accrued_And_O1

Accounts Payable, Accrued And Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable, Accrued and Other Liabilities	'
		June 30,		December 31,
		2014		2013
	Accounts payable and accrued expenses	$	1,922,716	$	1,868,534
	Interest accruals		2,433,654		2,214,760
	Total	$	4,356,370	$	4,083,294

Short_Term_Loans_Tables

Short Term Loans (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Short Term Loan	'
		June 30,		December 31,
		2014		2013
	Bridge Loan	$	2,000,000	$	2,000,000
	RIGHT loan		294,333		311,159
	Bryan Sanders loan		30,000		30,000
	Total		2,324,333		2,341,159
Schedule of Lenders of Bridge Loan	'
	The loan providers are the followings:
	Name	Bridge Amount
	SBIC Investors
	Trident	$	1,100,000
	Non-SBIC Investors
	Andy Browder		25,000
	Proto Investments		250,000
	Ford Sasser		25,000
	Danny Vela		25,000
	Steve Walton		150,000
	Hilton Wilson		25,000
	Will Wilson		250,000
	Rodman & Renshaw		150,000
		$	2,000,000

General_Information_Summary_Of

General Information (Summary Of Purchase Price Consideration) (Details) (Genetic Immunity, Inc, USD $)	0 Months Ended
	Oct. 02, 2012
Genetic Immunity, Inc	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'
Purchase price (at par value)	$1
Fair value adjustment of shares	$25,072,621
Total purchase price	$25,073,621

General_Information_Schedule_O

General Information (Schedule Of Purchase Price Allocation) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Aug. 29, 2007	Apr. 25, 2006	Oct. 02, 2012
							Genetic Immunity, Inc
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Cash	$20,862	$22,922	$65,586	$63,986	'	'	$357,276
Inventories	21,527	22,651	'	'	'	'	13,843
Other receivables	'	'	'	'	'	'	306,731
Intangibles	30,029,350	30,055,381	'	'	'	'	30,111,909
Fixed assets	147,329	189,194	'	'	'	'	418,483
Accounts payable and accrued liabilities	4,356,370	4,083,294	'	'	'	'	1,893,833
Grants received	-1,360,935	-1,432,042	'	'	'	'	-1,677,348
Short term loans to related parties	73,907	86,899	'	'	'	'	154,631
Bridge loan	'	'	'	'	2,000,000	'	2,334,326
Other liabilities	'	'	'	'	'	'	73,483
Total purchase price	'	'	'	'	'	'	$25,074,621

Other_Receivables_Details

Other Receivables (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Receivables Details	'	'
Taxes reclaimable	$53,154	$10,940
Advances given	134,820	178,075
Other	213	28,404
Total	$188,187	$217,419

Intangibles_And_Fixed_Assets_F

Intangibles And Fixed Assets (Fixed Assets) (Details) (USD $)	6 Months Ended	8 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2006	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'
Change in FX rates	$113,536	$4,151	($159,653)	($37,272)	($13,791)	($38,874)	$17,823	$36,465	($14,001)
Property and equipment net book value	147,329	'	189,194	'	'	'	'	'	'
Machinery and Other Equipments	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'
Property and equipment gross book value opening balance	677,434	'	599,765	'	'	'	'	'	'
Corrections	'	'	376,769	'	'	'	'	'	'
Additions	'	'	1,471	'	'	'	'	'	'
Disposals	'	'	-324,837	'	'	'	'	'	'
Change in FX rates	-39,140	'	24,266	'	'	'	'	'	'
Property and equipment gross book value closing balance	638,294	'	677,434	'	'	'	'	'	'
Accumulated depreciation and amortization opening balance	547,769	'	172,722	'	'	'	'	'	'
Corrections	'	'	376,770	'	'	'	'	'	'
Additions	29,968	'	79,744	'	'	'	'	'	'
Disposals	'	'	-95,121	'	'	'	'	'	'
Change in FX rates	-30,199	'	13,654	'	'	'	'	'	'
Accumulated depreciation and amortization closing balance	547,538	'	547,769	'	'	'	'	'	'
Property and equipment net book value	90,756	'	129,665	427,043	'	'	'	'	'
Vehicles	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'
Property and equipment gross book value opening balance	327,781	'	319,833	'	'	'	'	'	'
Corrections	'	'	'	'	'	'	'	'	'
Additions	'	'	'	'	'	'	'	'	'
Disposals	'	'	'	'	'	'	'	'	'
Change in FX rates	-16,276	'	7,948	'	'	'	'	'	'
Property and equipment gross book value closing balance	311,505	'	327,781	'	'	'	'	'	'
Accumulated depreciation and amortization opening balance	268,252	'	243,707	'	'	'	'	'	'
Corrections	'	'	'	'	'	'	'	'	'
Additions	'	'	18,489	'	'	'	'	'	'
Disposals	'	'	'	'	'	'	'	'	'
Change in FX rates	-13,320	'	6,056	'	'	'	'	'	'
Accumulated depreciation and amortization closing balance	254,932	'	268,252	'	'	'	'	'	'
Property and equipment net book value	56,573	'	59,529	76,126	'	'	'	'	'
Total Net property and equipment	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'
Property and equipment gross book value opening balance	1,005,215	'	919,598	'	'	'	'	'	'
Corrections	'	'	376,769	'	'	'	'	'	'
Additions	'	'	1,471	'	'	'	'	'	'
Disposals	'	'	-324,837	'	'	'	'	'	'
Change in FX rates	-55,416	'	32,214	'	'	'	'	'	'
Property and equipment gross book value closing balance	949,799	'	1,005,215	'	'	'	'	'	'
Accumulated depreciation and amortization opening balance	816,021	'	416,429	'	'	'	'	'	'
Corrections	'	'	376,770	'	'	'	'	'	'
Additions	29,968	'	98,233	'	'	'	'	'	'
Disposals	'	'	-95,121	'	'	'	'	'	'
Change in FX rates	-43,519	'	19,710	'	'	'	'	'	'
Accumulated depreciation and amortization closing balance	802,470	'	816,021	'	'	'	'	'	'
Property and equipment net book value	$147,329	'	$189,194	$503,169	'	'	'	'	'

Intangibles_And_Fixed_Assets_I

Intangibles And Fixed Assets (Intangibles) (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Intangibles And Fixed Assets Intangibles Details	'	'	'
Gross book value opening balance	$30,612,186	$30,115,115	'
Corrections	'	480,491	'
Additions	'	11,329	'
Disposals	'	'	'
Change in FX rates	-11,317	5,251	'
Gross book value closing balance	30,600,869	30,612,186	'
Accumulated depreciation and amortization opening balance	556,805	22,274	'
Corrections	'	480,491	'
Additions	26,465	50,914	'
Disposals	'	'	'
Change in fx rates	-11,751	3,126	'
Accumulated depreciation and amortization closing balance	571,519	556,805	'
Net book value	$30,029,350	$30,055,381	$30,092,841

Capital_Leases_Payable_Schedul

Capital Leases Payable (Schedule Of Future Minimum Leases Payment) (Details) (USD $)	Jun. 30, 2014
Capital Leases Payable Schedule Of Future Minimum Leases Payment Details	'
2014	$49,867
2015	23,058
Total minimum lease payment	72,925
Less: amount representing interest	3,479
Present value of net minimum lease payments	69,446
Less: current portion	-69,446
Long term liability	'

Stockholders_Equity_Schedule_O

Stockholders' Equity (Schedule Of Fair Value of Liabilities) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Financial liabilities	'	'
Liabilities measured at fair value	$91,480	$87,502
Fair value of warrant per share	'	'
Per share	$0.04	$0.02
Book Value	'	'
Financial liabilities	'	'
Liabilities measured at fair value	91,480	87,502
Fair Value	'	'
Financial liabilities	'	'
Liabilities measured at fair value	$91,480	$87,502

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Fair Value Estimation) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Current share price	$0.07
Exercise price	$0.10
Expected time to expiry (years)	'4 years 3 months
Expected dividend yield	0.00%
Volatility	50.00%
FED Prime Rate	'
Risk free rate	3.25%

Accounts_Payable_Accrued_And_O2

Accounts Payable, Accrued And Other Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accounts Payable Accrued And Other Liabilities Details	'	'
Accounts payable and accrued expenses	$1,922,716	$1,868,534
Interest accruals	2,433,654	2,214,760
Total	$4,356,370	$4,083,294

Short_Term_Loans_Schedule_Of_S

Short Term Loans (Schedule Of Short Term Loan) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Short Term Loans	$2,324,333	$2,341,159
Bridge Loan	'	'
Short Term Loans	2,000,000	2,000,000
RIGHT Loan	'	'
Short Term Loans	294,333	311,159
Bryan Sanders loan	'	'
Short Term Loans	$30,000	$30,000

Short_Term_Loans_Schedule_Of_L

Short Term Loans (Schedule Of Lenders Of Bridge Loan) (Details) (USD $)	Aug. 29, 2007
Bridge Loan Amount	$2,000,000
SBIC Investors - Trident	'
Bridge Loan Amount	1,100,000
Non SBIC Investors - Andy Browder	'
Bridge Loan Amount	25,000
Non SBIC Investors - Proto Investments	'
Bridge Loan Amount	250,000
Non SBIC Investors - Ford Sasser	'
Bridge Loan Amount	25,000
Non SBIC Investors - Danny Vela	'
Bridge Loan Amount	25,000
Non SBIC Investors - Steve Walton	'
Bridge Loan Amount	150,000
Non SBIC Investors - Hilton Wilson	'
Bridge Loan Amount	25,000
Non SBIC Investors - Will Wilson	'
Bridge Loan Amount	250,000
Non SBIC Investors - Rodman and Renshaw	'
Bridge Loan Amount	$150,000

General_Information_Narrative_

General Information (Narrative) (Details) (USD $)	6 Months Ended	12 Months Ended	1 Months Ended		0 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Nov. 30, 2013	Jan. 02, 2014	Oct. 02, 2012
			Series D Preferred Stock	Genetic Immunity	Genetic Immunity
			Director Peter Boros	Common Stock	Series B Preferred Stock
No of shares issued in business acquisition	'	'	'	'	1,000,000
Value of shares issued in business acquisition, per share	'	'	'	'	$25.07
Conversion of preferred stock into common stock	'	'	'	40,000,000	'
Percentage of ownership	'	'	'	100.00%	'
Loan amount converted for shares	'	'	$337,657	'	'
Share issued for debt conversion	'	'	1,000,000	'	'
Total proceeds from private placement of common and preferred stock	$377,949	$401,500	'	'	'

General_Information_IGlue_Soft

General Information (IGlue Software) (Narrative) (Details)

0 Months Ended

22 Months Ended

34 Months Ended

22 Months Ended

34 Months Ended

Nov. 23, 2011

Nov. 03, 2011

19-May-11

17-May-10

Jan. 08, 2009

Nov. 23, 2011

31-May-09

17-May-10

Aug. 02, 2007

31-May-09

17-May-10

Aug. 02, 2007

Investment in in4, Ltd

Investment in in4, Ltd

Investment in in4, Ltd

Investment in in4, Ltd

iGlue

USD

USD

USD

HUF Currency

HUF Currency

HUF Currency

Investment in in4, Ltd

Investment in in4, Ltd

Investment in in4, Ltd

Investment in in4, Ltd

Investment in in4, Ltd

Investment in in4, Ltd

USD ($)

USD ($)

USD ($)

HUF

HUF

HUF

Percentage of equity investment by Vidatech Kft

'

'

'

'

'

'

'

'

30.00%

'

'

'

Investment by Vidatech Kft

'

'

'

'

'

'

'

'

$5,000

'

'

900,000

Member loan from Vidatech

'

'

'

'

'

'

271,000

'

'

48,000,000

'

'

Conversion of member loan agreement

'

'

'

'

'

'

'

'

'

'

'

'

As part of the agreement, Vidatech had the option of converting its HUF 48 million member loan into an additional 10% equity in in4 Kft. on or before the end of May, 2009. As of January 8, 2009 the Company has elected to covert our member loan into the additional 10% equity in in4, Ltd., resulting in Vidatech owning 40% of equity.

Transfer of ownership

'

'

'

'

'

'

'

'

'

'

'

'

Company transferred its equity ownership from its Hungarian subsidiary Vidatech, Kft. to Power of the Dream Ventures. The transfer was initiated to prepare for its eventual exit from iGlue.

Additional investment

'

'

'

'

'

'

'

310,000

'

'

64,000,000

'

Total investment

'

'

'

'

'

'

'

600,000

'

'

112,000,000

'

Investment by new investor

'

'

'

'

'

'

'

$550,000

'

'

110,000,000

'

Equity allotment for new investor funding

'

'

'

'As part of the new round of fund raising the Company agreed to convert its HUF 60 million in member loan into 3% equity. Following this conversion the new investor received 10% in in4, Ltd., of which the Company provided 1.5% and Peter Vasko, Founder of in4 limited provided 8.5%.

'

'

'

'

'

'

'

'

On May 19 of 2011 a new member joined in4, Ltd, Zoltan Siklosi who received 3% equity in the company for services rendered

Ownership position in in4Ltd after new investor funding

'

'

'

'

'

'

'

'

'

'

'

'

Following his entry the new equity structure of the company changed to Peter Vasko owning 48.5% percent, Gyorgy Markos owning 10%, Zoltan Siklosi owning 3% and Power of the Dream Ventures owning 38.5%.

Following the fund raising the new equity positions in in4 changed to Peter Vasko owning 51.5% (down from the pre-transaction 60%), Power of the Dream Ventures owning 38.5% (down from the pre-transaction 40%) and the new investor owning 10% equity.

Merger agreement terms

'

'

'

'

'

'

'

'

'

'

'

'

in4, Ltd signed a Definitive Share Exchange Agreement to merge with Hardwired Interactive (HDWR) a fully reporting public company. As part of this agreement all holders of in4, Ltd equity received common and preferred stock in the newly public entity. As part of the transaction we received 600,000 shares of Series B Hardwired Interactive common stock convertible into 6,000,000 shares of common stock upon a reverse stock split. The Company also received warrants to purchase a total of three million shares of post split common stock, one million shares each at $5 dollars, $7 dollars and $9 dollars per share.

Dividend

'

'

'

'

'

'

'

'

'

'

'

'

Company announced plans to provide a dividend, in the form of iGlue common stock, to PWRV shareholders of record on December 23, 2011. Each PWRV share was to receive 0.05 share of iGlue common stock in the dividend

Share holding of iGlue after dividend

'

'

'

'

'

'

'

'

'

'

'

'

Company still holds 2,884,986 shares of iGlue common stock and warrants to purchase a total of three million addition shares.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Narrative) (Details)	6 Months Ended
	Jun. 30, 2014
Series C Preferred Stock	'
Preferred shares of conversion terms	'
		-	1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis.
Series E Preferred Stock	'
Preferred shares of conversion terms	'
	450,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 4,500,000 common stock on a fully converted basis
MinimumMember	'
Estimated useful lives of the various classes of long-lived assets	'3 years
MaximumMember	'
Estimated useful lives of the various classes of long-lived assets	'7 years

Other_Receivables_Narrative_De

Other Receivables (Narrative) (Details) (General and Administrative Expense, USD $)	12 Months Ended
	Dec. 31, 2013
General and Administrative Expense	'
Impairment of advances	$88,117

Research_And_Development_Narra

Research And Development (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended		98 Months Ended	83 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
						Investment in in4, Ltd	Investment in FireLess
Investment considered as research and development	'	'	'	'	$866,619	$5,000	$900
Loan considered as research and development	'	'	'	'	'	$310,000	'

Note_Payable_Narrative_Details

Note Payable (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended		6 Months Ended	12 Months Ended	6 Months Ended	0 Months Ended
	Apr. 10, 2007	31-May-09	Nov. 30, 2008	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jul. 19, 2011	Dec. 04, 2012	Sep. 30, 2012	Mar. 16, 2011
	Notes Payable - Mary Passalaqua	Notes Payable - Mary Passalaqua	Notes Payable - Mary Passalaqua	Notes Payable - Mary Passalaqua	Notes Payable - Mary Passalaqua	Notes Payable - Mary Passalaqua	Promissory Note - Infinite Funding	Convertible Promissory Note - Infinite Funding	Convertible Promissory Note - Infinite Funding	Convertible Promissory Note - Infinite Funding
						FED Prime Rate
Debt amount	$250,000	'	'	'	'	'	$49,000	'	'	$76,000
Debt maturity date	5-Apr-08	'	'	'	'	'	'	31-Dec-12	'	5-Dec-11
Debt maturity date, extended	5-Apr-09	'	'	'	'	'	'	'	'	'
Repayment of notes payable	'	20,000	35,000	'	'	'	'	'	'	'
Debt instrument interest rate	'	'	'	'	'	3.25%	12.00%	'	'	10.00%
Debt instrument interest expenses	'	'	'	$54,123	$52,417	'	'	'	'	'
Conversion price of debt	'	'	'	'	'	'	'	'	$0.04	$0.05
Share issued for debt conversion	'	'	'	'	'	'	'	'	1,900,000	'

Capital_Lease_Payable_Narrativ

Capital Lease Payable (Narrative) (Detail) (Capital Lease)	1 Months Ended
	Sep. 30, 2009	Dec. 31, 2008	Dec. 31, 2007	Aug. 31, 2007
Capital Lease	'	'	'	'
Description of capital lease arrangements	'	'In December 2008, the Company settled the capital lease agreements on 2 vehicles and replaced them with new agreements for additional 2 vehicles, totaling 5 capital lease agreements at December 31, 2008. The maturity of the new leases varies from 60 to 72 months and are denominated in EUR and CHF. Installments and interests are due on a monthly basis.	'In December, 2007, the Company entered into additional capital lease agreements on 2 vehicles for management purposes. The maturity of the lease is 72 months and is denominated in CHF. Installments and interest is due on a monthly basis.	'In August, 2007, the Company entered into capital lease agreements on 3 vehicles for management purposes. The maturity of the lease is 60 months and is denominated in CHF. Installments and interest is due on a monthly basis.
	Company closed a capital lease agreement for one vehicle. The related asset has been sold.

Stockholders_Equity_Narrative_

Stockholder's Equity (Narrative) (Details)	Jun. 30, 2014	Dec. 31, 2013	Oct. 26, 2011	Oct. 26, 2011	Oct. 26, 2011	Oct. 26, 2011	Oct. 26, 2011
			Series A Preferred Stock	Viktor Rozsnyay	Viktor Rozsnyay	Daniel Kun Jr	Daniel Kun Jr
				Series A Preferred Stock	Common Stock	Series A Preferred Stock	Common Stock
Common stock returned to treasury	'	'	'	'	12,000,000	'	12,000,000
Preferred stock issued	5,450,000	4,900,000	2,000,000	1,000,000	'	1,000,000	'

Stockholders_Equity_Private_Pl

Stockholder's Equity (Private Placement) (Narrative) (Details) (USD $)

6 Months Ended

12 Months Ended

98 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2007

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

28-May-14

Apr. 28, 2014

Apr. 07, 2014

Feb. 19, 2014

Nov. 01, 2013

Oct. 17, 2013

Sep. 26, 2013

Sep. 25, 2013

9-May-13

Apr. 03, 2013

Jun. 13, 2012

Jun. 30, 2012

Nov. 14, 2011

Sep. 02, 2011

Aug. 29, 2011

Jun. 30, 2011

Sep. 30, 2010

Jun. 30, 2010

Jun. 30, 2010

Feb. 28, 2010

Nov. 30, 2009

Nov. 30, 2009

Nov. 30, 2009

Oct. 31, 2008

Jan. 31, 2008

Oct. 31, 2007

Jun. 30, 2007

Series E Preferred Stock

Series C Preferred Stock

Private Placement to Two Unaffiliated Private Investors, May 28, 2014

Private Placement to One Unaffiliated Private Investor, April 28, 2014

Private Placement to One Unaffiliated Private Investor, April 7, 2014

Private Placement to Two Unaffiliated Private Investors, February 19, 2014

Private Placement to One Unaffiliated Private Investor, November 1, 2013

Private Placement to One Unaffiliated Private Investor, October 17, 2013

Private Placement to Two Unaffiliated Private Investors, September 26, 2013

Private Placement to One Unaffiliated Private Investors, September 25, 2013

Private Placement to an Unaffiliated Private Investor, May 9, 2013

Private Placement to an Unaffiliated Private Investor, April 3, 2013

Private Placement to an Unaffiliated Private Investor, June 13,2012

Private Placement First Half of 2012

Private Placement to an Unaffiiated Private Investor, November 14, 2011

Private Placement to Two Unaffiliated Private Investors, September 2, 2011

Private Placement to One Unaffiliated Private Investor, August 29, 2011

Private Placement Second Quarter of 2011

Private Placement Third Quarter of 2010

Private Placement First Half of 2010

Private Placement on First Half of 2010

Private Placement February 2010

Private Placement November 2009

Private Placement November 2009

Private Placement November 2009

Private Placement October 2008

Private Placement January 2008

Private Placement October 2007

Private Placement June 2007

Series E Preferred Stock

Series C Preferred Stock

Series E Preferred Stock

Series E Preferred Stock

Series D Preferred Stock

Series C Preferred Stock

Series C Preferred Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Subsidiary, Sale of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued for private placement

'

'

'

'

'

'

'

'

'

200,000

100,000

50,000

200,000

'

250,000

650,000

1,000,000

100,000

1,400,000

42,200

'

27,700

1,727,013

17,825

196,489

70,000

1,470,000

62,500

65,000

175,000

111,110

175,000

2,500,000

32,500

104,000

2,250,000

Share issue price

'

'

$0.15

$0.10

$0.40

$2.50

'

'

'

'

'

'

'

'

'

'

'

$0.04

$0.04

$0.30

'

$0.16

$0.16

$0.12

$0.29

$0.50

$0.10

$0.08

$0.12

$0.16

$0.20

'

$0.40

$3.25

$2.50

$0.34

Proceeds from stock issue

'

$52,500

'

'

'

'

$2,885,249

'

'

$100,000

$27,949

$50,000

$200,000

'

$75,000

$195,000

$80,000

$3,500

$49,000

$12,658

$67,153

$4,432

$276,322

$2,137

$56,983

$35,000

$147,000

$5,000

$7,701

'

'

$50,222

$1,000,000

$105,625

$260,000

'

Subscription receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

765,000

Sale of stock transaction date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9-May-13

3-Apr-13

13-Jun-12

'

14-Nov-11

2-Sep-11

29-Aug-11

'

'

'

'

'

'

'

'

'

'

'

'

Preferred shares convertible description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

450,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 4,500,000 common stock on a fully converted basis

-

1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis.

Each share of Series E Preferred stock is convertible into 10 shares of common stock.

The Series D preferred stock is convertible into 2,000,000 shares of our common stock on a fully converted basis. No special redemption rights.

Preferred shares voting rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Each one share of the Series E Preferred has voting rights equal to five votes of common Stock

Preferred shares dividend

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The holders of Series E Preferred Stock are entitled to receive dividends equal to the amount that would be received if each one share of Series E Preferred stock was fully converted into twelve and one half shares of the common stock

Debt amount converted for shares

'

'

'

'

'

'

'

'

'

'

'

'

'

$337,653

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share issued for debt conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Consulting

Stockholder's Equity (Consulting Agreements) (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

98 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

2 Months Ended

0 Months Ended

2 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2007

Jun. 30, 2014

Dec. 31, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2012

Apr. 11, 2012

Oct. 31, 2011

Oct. 31, 2011

Oct. 31, 2011

Sep. 27, 2011

31-May-11

31-May-11

31-May-11

Feb. 07, 2011

Feb. 09, 2011

Feb. 24, 2011

Nov. 30, 2010

Sep. 30, 2010

Jun. 30, 2010

Apr. 30, 2009

Jun. 30, 2007

Apr. 30, 2007

Apr. 30, 2007

Common Stock

Four Unaffiliated Professionals November 2012

Four Unaffiliated Professionals November 2012

Four Unaffiliated Professionals November 2012

Stockvest April 11, 2012

Three Unaffiliated Professionals October 2011

Three Unaffiliated Professionals October 2011

Three Unaffiliated Professionals October 2011

Two Unaffiliated Professionals September 27, 2011

Five Unaffiliated Professionals April and May 2011

Five Unaffiliated Professionals April and May 2011

Five Unaffiliated Professionals April and May 2011

Unaffiliated Person February 7, 2011

Unaffiliated Person February 9, 2011

Unaffiliated Person February 24, 2011

Several Unaffiliated Professionals September 2010

Four Unaffiliated Professionals September 2010

Two Unaffiliated Professionals June 2010

Two Unaffiliated Professionals April 2009

Five Consultant Member June 2007

Two Professional for Legal Services April 2007

Inventors Research and Development April 2007

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

MinimumMember

MaximumMember

MinimumMember

MaximumMember

MinimumMember

MaximumMember

Share-based Goods and Nonemployee Services Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

1,930,000

'

'

135,000

640,000

'

'

100,000

505,000

'

'

215,000

435,000

75,000

874,000

153,000

20,000

250,000

1,375,000

500,000

100,000

Share issue price

'

'

'

'

'

$0.15

$0.10

$0.40

$2.50

'

'

'

$0.06

$0.19

'

'

$0.09

$0.11

$0.14

'

$0.34

$0.48

$0.30

$0.24

$0.30

$0.50

$0.50

$0.10

$0.40

$0.34

$0.34

$0.34

Stock issue expenses

'

'

'

'

'

$81,000

$54,000

$280,000

$2,590,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$467,501

'

'

General administration

198,502

347,591

395,612

503,058

'

'

'

'

'

9,290,844

'

180,170

'

'

'

61,200

'

'

14,000

190,900

'

'

64,500

104,400

22,500

437,000

76,500

2,000

100,000

'

170,000

'

Research and development expenses

'

'

'

'

'

'

'

'

'

866,619

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,000

Common stock issue date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11-Apr-12

'

'

'

27-Sep-11

'

'

'

7-Feb-11

9-Feb-11

24-Feb-11

'

'

'

'

'

'

'

Service contract duration

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'12 months

'

'

'12 months

'12 months

'

'

'12 months

'12 months

'12 months

'12 months

'12 months

'

'

'12 to 24 months

'

'

Type of service provided

'

'

'

'

'

'

'

'

'

'

'

'Business Consulting Services

'

'

'IR Services

'Consulting Services

'

'

'Business Consulting Service

'Consulting Services

'

'

'General Business Development And Incubation Consultation

'Services In Terms Of Potential Business Opportunities In Poland

'General Business Development And Incubation Consultation

'Consulting Services

'Consulting Services

'Consulting Services

'Consulting Services

'General Business Consulting Services

'Legal Services

'Research and Development

Shares cancelled

'

'

'

'

'

'

'

'

'

'

-250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expenses for stock issued during the year 2011

'

'

0

'

'

'

'

'

'

316,098

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expenses for stock issued during the year 2010

'

'

0

'

312,972

'

'

'

'

513,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expenses for stock issued during the year 2007

'

'

$0

'

$0

'

'

'

'

$467,501

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Other_Agre

Stockholder's Equity (Other Agreements) (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

98 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Jun. 30, 2014

Apr. 18, 2008

Apr. 18, 2008

17-May-08

Oct. 18, 2010

Sep. 10, 2012

Oct. 08, 2008

Sep. 10, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Oct. 18, 2010

Oct. 08, 2008

Media4Equity Inc Agreement On April 18, 2008

RedChip Companies Inc Agreement On April 18, 2008

Wakabayashi Fund LLC Agreement On May 17, 2008

Warrant

Warrant

Warrant

Warrant

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Restricted Stock

Restricted Stock

Restricted Stock

Y A Global Investment, L P

Y A Global Investment, L P

Y A Global Investment, L P

Bluestar Consulting

Y A Global Investment, L P

Y A Global Investment, L P

Common stock value agreed to sell

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

Warrant issued and outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,977,386

3,977,386

4,027,386

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

$0.10

'

'

'

'

'

'

'

'

'

Warrant expiry date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8-Oct-13

'

'

'

'

'

'

'

'

8-Oct-13

Warrants transfered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The new owner, Bluestar Consulting, now has the right to acquire, on or before October 8, 2013, 3,977,386 share of common stock at a per share exercise price of $0.10. The terms of the warrants are such that the exercise price was lowered due to a subsequent round of financing, from $0.29 per share to the price the subsequent investors paid, $0.10 per share.

Terms of the agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Pursuant to the terms of the Standby Equity Distribution Agreement, the Company (a) agreed to issue and sell to the Investor up to $5,000,000 of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") in tranches of equity, based upon a 7% discount to the market price of the Common Stock, calculated over the five trading days following notice by the Company of an election to sell shares; and (b) issued to the Investor a warrant (the "Warrant") to purchase 4,027,386 shares of Common Stock at the exercise price per share of $0.29.

Shares issued for service

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

2,065,000

1,970,000

1,047,000

250,000

1,917,681

1,875,000

'

2,000,000

Share issue price

'

'

'

'

'

$0.15

$0.10

$0.40

'

$2.50

'

$0.75

$0.70

$1.35

'

'

'

'

'

'

'

'

'

'

'

'

$0.40

Commitment fees adjusted against share issue

'

'

'

19,900

19,900

'

'

40,000

'

170,000

4,256,158

'

'

'

'

'

'

'

100

1,944

197

102

25

192

188

'

800,000

Warrant exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

Warrant converted to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

655,652

1,900,000

5,900,000

'

'

'

'

3,226

'

Restricted common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

1,500,000

306,570

111,111

'

'

'

'

'

'

'

'

'

'

'

'

'

Service agreement amount expensed out

198,502

347,591

395,612

503,058

'

'

'

'

'

'

9,290,844

1,125,000

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Service contract duration

'

'

'

'

'

'

'

'

'

'

'

'12 months

'12 months

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of share based compensation expenses towards wakabayashi fund llc stock issue

'

'

0

'

0

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of share based compensation expenses toward redchip and media4equity share issue

'

'

$0

'

$0

'

'

'

'

'

$1,339,599

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Stock_Base

Stockholder's Equity (Stock Based Compensations) (Narrative) (Details) (USD $)

6 Months Ended

12 Months Ended

98 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2007

Jun. 30, 2014

Jan. 02, 2011

Feb. 05, 2009

Oct. 24, 2007

Jun. 30, 2010

Jan. 02, 2011

Feb. 05, 2009

Oct. 01, 2007

Jun. 30, 2010

Jan. 02, 2011

Feb. 05, 2009

Oct. 24, 2007

Jun. 30, 2010

Jan. 02, 2011

Feb. 05, 2009

Oct. 24, 2007

Jun. 30, 2010

Jan. 02, 2011

Jun. 30, 2010

Jul. 15, 2009

Feb. 05, 2009

Oct. 24, 2007

Oct. 01, 2007

Oct. 24, 2007

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Ildiko Rozsa

Ildiko Rozsa

Ildiko Rozsa

Ildiko Rozsa

Szilvia Toth

Szilvia Toth

Szilvia Toth

Szilvia Toth

Imre Eotvos

Imre Eotvos

Imre Eotvos

Imre Eotvos

Daniel Kun Jr

Daniel Kun Jr

Daniel Kun Jr

Daniel Kun Jr

Gene Guhne

Gene Guhne

Mihaly Zala

Mihaly Zala

Mihaly Zala

Sandorne Juhasz

Viktor Rozsnyay

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares granted

'

'

'

'

'

'

'

100,000

120,000

250,000

100,000

100,000

120,000

100,000

100,000

120,000

200,000

25,000

120,000

120,000

200,000

250,000

120,000

100,000

100,000

'

120,000

150,000

11,000

250,000

Shares vested on grant

'

'

'

'

'

'

'

'

'

100,000

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000

'

Shares vested on each duration

'

'

'

'

'

'

'

25,000

30,000

30,000

25,000

25,000

30,000

10,000

25,000

30,000

50,000

5,000

30,000

30,000

50,000

50,000

30,000

25,000

25,000

'

30,000

30,000

750

50,000

Cancellation of shares granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

Share vesting frequency

'

'

'

'

'

'

'

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

'At the end of each quarter

Stock based compensation share issued

'

'

540,000

540,000

700,000

1,036,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation share price

'

'

$0.15

$0.10

$0.40

$2.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation value

'

'

$81,000

$54,000

$280,000

$2,590,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of stock based compensations share cost issued during the year 2007

$0

$0

'

'

'

'

$2,590,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Reverse_Me

Stockholder's Equity (Reverse Merger) (Narrative) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 10, 2007	Oct. 20, 2011	Aug. 05, 2011	Dec. 28, 2006	Mar. 31, 2007
				Reverse Merger With Vidatech	Mary Passalaqua Convertible Promissory Note	Mary Passalaqua Convertible Promissory Note	Short Term Loan	Short Term Loan
							Viktor Rozsnyay	Daniel Kun Jr
Debt face amount	'	'	'	'	$125,000	$195,000	'	'
Debt amount converted for shares	'	'	'	'	20,000	70,000	'	'
Share issued for debt conversion	'	'	'	'	3,600,000	2,400,000	'	'
Debt amount outsatnding	'	'	'	'	105,000	125,000	'	'
Short tem loan agreement date	'	'	'	'	'	'	'2006-05	'2007-03
Short term loan maturity date	'	'	'	'	'	'	30-Apr-07	31-Mar-07
Loan converted to equity	'	'	'	'	'	'	96,100	53,735
No of shares of pdv's common stock remained outstanding	46,500,896	46,500,896	42,495,244	2,500,000	'	'	'	'
No of shares issued in connection with merger	'	'	'	33,300,000	'	'	'	'
Short term loans from related parties	$73,907	$86,899	'	'	'	'	'	'

Short_Term_Loans_Narrative_Det

Short Term Loans (Narrative) (Details) (USD $)	Aug. 29, 2007	Aug. 29, 2007	Aug. 27, 2007
		SBIC Investors - Trident	Bridge Loan
Bridge loan amount	$2,000,000	$1,100,000	'
Interest rate on loan	'	'	12.00%
Debt repayment terms	'	'	'According to the loan agreement, the company settles the loan principal on the earlier of August 29, 2009 or consummation of a qualifying transaction other than reverse merger effected by the Company in completion of or in connection with a Public Offering. In case of late payment, the Company is liable to pay 18% late interest fee.

Other_Expenses_Narrative_Detai

Other Expenses (Narrative) (Details) (USD $)	6 Months Ended		98 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Liability from warrant	$3,978	($568,766)	$91,480
Bluestar Consulting	'	'	'
Liability from warrant	$3,978	'	'

Contingencies_Narrative_Detail

Contingencies (Narrative) (Details)

3 Months Ended

6 Months Ended

98 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Nov. 18, 2013

Feb. 13, 2013

Dec. 31, 2009

Nov. 18, 2013

Feb. 18, 2013

Feb. 13, 2013

Dec. 31, 2009

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Genetic Immunity

Genetic Immunity

Genetic Immunity

Genetic Immunity

Genetic Immunity

Genetic Immunity

Genetic Immunity

National Development Agency of Hungary

National Development Agency of Hungary

National Development Agency of Hungary

HUF Currency

HUF Currency

HUF Currency

HUF Currency

USD ($)

USD ($)

National Development Agency of Hungary

National Development Agency of Hungary

National Development Agency of Hungary

National Development Agency of Hungary

HUF

HUF

HUF

HUF

Research grant

$61,358

($266)

$34,859

$28,516

$311,838

'

'

$4,000,000

'

'

'

800,000,000

Lawsuit costs

'

'

'

'

'

'

'

'

'

250,000

52,500,000

'

Damages sustained claim

'

'

'

'

'

'

$20,000,000

'

4,800,000,000

'

'

'

Law suit status

'

'

'

'

'

'On November 18, 2013, the Company has entered into a six month suspension of said lawsuit, as agreed with the government, in hopes of negotiating an out of court settlement. After the lapse of our six month suspension we once again resumed the trial as the Company could not arrive at an out of court settlement. The Company currently awaits a court date for the trial to continue, but in the mean time is still working towards an out of court settlement and the closing of this law suite.

'

'

'

'

'

'